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A BRIEF ACCEPTANCE AND COMMITMENT THERAPY PROTOCOL
FOR DEPRESSION IN AN INPATIENT SETTING:
AN EFFECTIVENESS STUDY

Lucas A. Broten, Ph.D.
Western Michigan University, 2013

The present study sought to investigate the utility of a brief Acceptance and
Commitment Therapy (ACT) protocol for the treatment of depression in an inpatient
setting. ACT is a generally promising treatment for a variety of psychological issues.
Thirty-nine participants were randomly assigned using and weighted, blocked
distribution to either Treatment as Usual (TAU) or individual sessions of ACT in
conjunction with treatment as usual (ACT). The study compared re-admission rates
between the ACT intervention group and the TAU group at 3 and 6 months. In
addition, the study examined the proposed mechanisms of change between groups and
depression rates between groups.
No differences were found between the TAU and ACT groups with regard to the
primary outcome measure of re-hospitalization at 3- or 6-month follow-up.
Additionally, ACT did not appear to move depression measures or the proposed
mechanisms of action above and beyond the general improvement seen across the
sample when compared at the group level. Differences were found in favor of ACT on
one measure of mechanism of action proposed to be involved with ACT interventions,
the ATQ-B, when the percent of participants that had an RCI were examined by group.

This could indicate that ACT, when received, was better decreasing the believability of
thoughts.
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CHAPTER I
INTRODUCTION
Adult Depression
Major Depressive Disorder is a common psychological disorder. Lifetime
prevalence rates are estimated to be 16.2% in the United States with the point prevalence
estimated to be 6.6% (Kessler et al., 2003). Furthermore, results from the Kessler and
colleagues (2003) survey suggest that younger generations appear to demonstrate earlier
and higher prevalence rates than previous birth cohorts, suggesting that depression may
be increasingly prevalent in the future. In fact, the World Health Organization estimates
that by 2020 depression will be second leading cause of disability worldwide (WHO,
2010). In addition, it has been reported that a large proportion of patients with Major
Depressive Disorder suffer a chronic (25%) or recurrent (75%) course (Rush et al., 2008),
and there is no evidence that antidepressants alter the course of depression (Dimidjian
et al., 2006). Since antidepressants do not appear to have enduring effects after use is
discontinued, patients may be at significant risk for relapse and recurrence (Hollon et al.,
2005).
Major Depressive Disorder
According to the Diagnostic and Statistical Manual of Mental Disorders
(DSM–IV–TR; American Psychiatric Association [APA], 2000a), Major Depressive
Disorder (MDD) involves a change in previous functioning marked by depressed mood
or loss of interest or pleasure in activities for a minimum of two weeks. Additionally, for
1
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a diagnosis of depression, several additional behavioral, cognitive, and physiological
symptoms must be present. These can include insomnia or hypersomnia, fatigue or loss
of energy, feelings of worthlessness or excessive and inappropriate guilt, social
withdrawal, diminished ability to think or concentrate, recurrent thoughts of death, or
suicidal ideation. When at least five of nine symptoms are present, one of which being
sadness, anhedonia, or irritability, a diagnosis of MDD applies. A diagnosis of MDD not
otherwise specified (NOS) may be made when symptoms are clinically significant but do
not meet the exact threshold for diagnosis, for example, a client who failed to endorse
depressed mood or anhedonia every day for two weeks but had other symptoms that were
clinically significant and related to depression. Also, many have come to suggest that
depressive symptoms are continuous rather than discrete and that even sub-threshold
symptoms are associated with functional impairment (Lewinsohn, Rohde, Seeley, Klein,
& Gotlib, 2000).
Behavioral Model of Depression
Ferster (1973) describes the first task of a behavioral interpretation of disorders as
“defining the behavior objectively, emphasizing functional classes of performance
consistent with prevailing clinical facts, the component behaviors of which can be
observed, classified and counted.” The function of this approach is to precisely define
and specify the behavioral phenomena that are occasioned by the term depression.
Additionally, as explicated by Kanter, Cautilli, Busch, and Baruch (2005), the term
depression does not precisely map onto any particular or set of particular behavioral or
empirical phenomenon and has no essential composition. Given the great amount of
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variance between individual symptoms tacted as having depression or being depressed, it
is important not to reify the term as an entity or explanation for symptoms but rather to
see it as, at best, a summary label.
A behavior analytic account of depression has been proposed to have seven
possible functional classes (Kanter et al., 2005). The first class of behavior is insufficient
levels of positive reinforcement as described by Lewinsohn (1974). This is best
described as low rate of response-contingent positive reinforcement (RCPR) due to
environmental factors. It is well known that loss of reinforcement may result in a
decrease or complete cessation of relevant behaviors altogether. This model emphasizes
major losses of RCPR such as death of a spouse or job loss, coupled with skills deficits
that limit an individual’s ability to (re-) obtain RCPR. Lack of positive reinforcement is
proposed to lead to behavioral reductions that are commonly observed in depressive
disorders. This finding is also essential to the empirically supported learned helplessness
model of depression (Overmier & Seligman, 1967). Affective components (dysphoric
reaction, fatigue) of the disorder are assumed to be elicited byproducts of behaviorenvironment interactions that result from insufficient levels or loss of RCPR. In addition
to the loss of RCPR, positive reinforcement of depressed behavior must also be taken into
account. Hopko, Lejuez, Ruggiero, and Eifert, (2003) analyzed depression in terms of
matching law (Herrnstein, 1970) in order to evaluate this aspect of the propagation and
maintenance of depression. This view necessitates the examination of the individual’s
environment for loss of RCPR and RCPR of depressed behaviors. As the availability of
reinforcers for adaptive behavior is decreased, control of non-depressed behavior by
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previous controlling stimuli weakens. Negative reinforcement may come to prevail as
the primary contingencies governing behavior, which leads to an increase in depressive
behaviors. An example of this would be a person with poor social skills that is punished
for attempts at pro-social behavior, leading to a decrease in these attempts. The
individual may complain about his or her depressive symptoms around others and may
actually re-gain this lost RCPR; however, now it is propagating depressive behavior.
Another manner in which RCPR can be reduced is ratio strain. It has been
demonstrated that the accrual of multiple minor stressors is often associated with
depression as opposed to major losses of reinforcement (Billings & Moos, 1984). This
might be interpreted as an example of ratio strain. The multiple stressors, especially
when increased rapidly, result in disruptions in responding that may appear similar to
extinction. As with extinction, this may result in depressive behaviors. For example, a
person that starts a new job does not know how to do the job competently and may be
reprimanded repeatedly at work. This sudden increase in minor stressors may result in
depressive behavior.
Finally, reinforcement erosion (Jacobsen & Margolin, 1979) refers to the process
of habituation and satiation to reinforcing stimuli. This describes loss of the
reinforcement properties, effectively decreasing the RCPR available although there is no
actual loss of access to these situations in the environment. This decrease could result in
a substantial loss of RCPR resulting in depressive behavior. One possible example is a
person that is in a new relationship may desire to spend all of their time with the person
as they find many of their behaviors and interactions to be rewarding. However, as the
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novelty of the relationship wears thin the person may not find these behaviors as
rewarding even though they may be spending just as much time with them as they did at
the beginning of the relationship.
The second functional class is an increase in punishment. Punishment by
definition reduces behavior. When punishment is generalized, such as through the failure
to display effective operant behavior over time resulting in extinction of entire classes of
operant behavior, chronic depression can result. As first espoused by Skinner (1953) and
later by Ferster (1973), depression is also characterized by increased escape and
avoidance behaviors. These are largely passive repertoires that often can contribute to
the decrease of RCPR through avoidance or escape from an environment that may
provide more opportunities for RCPR. Kanter, Busch, Weeks, & Landes (2008) suggest
that the core elicited affective experience of depression can be a product of an increase in
aversive control, especially aversive social control, as well as the associated decrease in
appetitive control. Maladaptive or over-expansive avoidance and escape maintained
behaviors are immediately effective but diminish access to RCPR in the long-term. This
results in further decrease in behaviors and increase in the affective experience of
depression as a byproduct of the environment behavior interaction. This has been
demonstrated in research with children and adolescents and suggests that depression may
be a function of negative reinforcement and high punishment density (Sheeber &
Sorenson, 1998).
Thirdly, positive reinforcement of depressive behavior such as social solicitation
of depressive behavior, complaining, reason giving, and expression of worry may help to
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maintain depression, especially in situations of low density reinforcement. As an
individual increases the social solicitation of depressive behavior as a result of positive
social reinforcement, those giving this reinforcement may gradually reduce contact with
the individual. This may be especially prevalent in cases where the individual also has a
deficit in social skills, which reduces positive reinforcement for the listener even further,
resulting in fewer opportunities for RCPR.
The fourth domain is negative reinforcement of depressive behaviors. Avoidance
or escape of environmental stimuli that may elicit aversive private events while also
reducing contact with potentially reinforcing stimuli negatively reinforces depressive
behavior. Additionally, depressive behavior can result in a decrease in aggressive
behavior from others toward the depressed individual (Biglan et al., 1985). By removing
aversive aggressive behaviors, like anger of a husband towards a wife or parent towards a
child, in response to depressive behaviors, the likelihood of further depressive behaviors
and statements is increased.
Rule-governed behavior is the fifth class of behavior that may have an impact on
depression. Both lack of appropriate rule-governed behavior as well as over-expansive
rule-governed behavior can be a maintaining variable of depression. Lack of rulegoverned behavior can be especially evident in weak rules (Malott, 1981) that have
delayed, incremental, or unpredictable outcomes. This lack of rule governance results in
insufficient contact with positive long-term consequences. This may result in overcontrol by immediate contingencies and over-reliance on avoidance or escape strategies,
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which can, in turn, result in long-term reduction in RCPR, e.g., a teen staying home from
school in order to avoid expected social ridicule.
Over expansive rule-governance can maintain depression by promoting
experiential avoidance (Hayes, Strosahl, & Wilson, 1999). This rule governance leads to
the long-term experiential avoidance repertoires and may allow them to persist in the face
of direct histories of reinforcement. This over-reliance on verbal rules related to
experiential avoidance may increase negative reinforcement in the short term while
preventing RCPR in the long term. For example, a rule such as “I can’t show when I am
sad” may result in avoiding school or social functions when feeling sad so as to keep their
feelings hidden from others. This avoidance would prevent the child from receiving the
natural social reinforcers that would occur at a party or hanging out with friends at
school. This is especially the case for the avoidance of negative private events, which,
according to Hayes et al. (1999), are not under the control of verbal rules. As such, rules
that promote avoidance or unwillingness to experience negative private events often lead
to solutions that limit RCPR in the long term and increase depressive behaviors in the
short term.
In addition to rule governance, growing research in relational frame theory (RFT;
Hayes, Barnes-Homes, & Roche, 2001) suggests that transformation of stimulus
functions resulting from the behavior of framing events relationally may play an
important role in the maintenance and propagation of depression. The implication is that
relations between behaviors, cognitions, and mood need not be directly trained in order to
become functionally connected. Therefore, vast arrays of cognitions, affective responses,
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and behaviors can take on the function of eliciting stimuli by merely being associated
verbally. This transfer of stimulus functions has been demonstrated in one type of
relation, stimulus equivalence, or the relation of sameness. Augustson and Dougher
(1997) have demonstrated that avoidance responding can be transferred through
equivalence class and for relations that were not explicitly trained. According to the
theory, stimulus function can also be transferred across other derived relational
responding such as opposition and more or less than. This suggests that the behavior of
relational framing has a transformative effect on the function of the stimuli in the
environment, altering the contingencies that would be in place if the derived relations
were not exerting control. This has a potential implication for treatment of depression
directed at altering environmental (Jacobsen et al., 1996). If relational framing and
transformation of stimulus functions are altering environmental contingencies in some
cases of depression, it may implicate the necessity of an alternate treatment approach
addressing the relational functions.
Finally, establishing operations may increase the likelihood of depressive
behaviors. Dougher and Hackbert (2000) describe depression in terms of establishing
operations and suggest that long-term and short-term establishing operations can be used
to describe setting events in depression. Setting events can be described as stimuli that
abolish non-depressive contingencies and establish depressive contingencies; for
example, a long history of child abuse where assertive behavior is punished may establish
such behavior as particularly aversive. This setting event may decrease the likelihood of
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assertive behavior that may result in RCPR and potentiate more passive behaviors that
are less likely to result in RCPR.
Treatment of Depression
Pharmacotherapy
Pharmacotherapy for depression is often a first line treatment for depressive
symptoms. In most instances, access to antidepressant medication is readily available in
primary care settings, unlike evidence-based psychosocial interventions, which generally
require a specialized therapist. Pharmacotherapy has been shown to be of use for acute
depressive symptoms and is initially cheaper and easier to initiate than an empirically
supported psychotherapeutic intervention (Domino et al., 2008; Elkin et al., 1989).
However, compliance with medication can often be an issue. In addition, the American
Psychiatric Association (APA, 2000b) suggests that psychiatric management consist of a
“broad array” of services including a diagnostic evaluation, evaluation of safety
(suicide/homicide), establishment and maintenance of the therapeutic alliance,
monitoring of symptoms, psychoeducation, and efforts to enhance treatment adherence,
which increases the cost and availability to the general public and is not typically
implemented in a primary care setting.
The Sequenced Treatment Alternatives to Relieve Depression (STAR*D; Rush
et al., 2008) study was designed to investigate the impact of sequenced treatment
strategies for pharmacotherapy and psychotherapy. The study implemented a SSRI
antidepressant (Citalopram) as the first step in the model of treatment. Those who failed
to respond to this initial step were then given the option of changing medications,
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changing to cognitive psychotherapy, augmenting medication with Cognitive Therapy, or
augmenting with another medication type. In total, 70% of those that completed the
stepped protocol achieved remission (Fawcett, 2008). However, many of the participants
needed several steps to achieve remission and those who required more steps showed
higher intolerance for treatment and higher relapse rates (Rush et al., 2008).
In spite of these positive results, studies have suggested that an initial response to
pharmacotherapy may not be as sustained as in Cognitive Behavioral Therapy (CBT)
(Hollon et al., 2005; Rohde et al., 2008). Additionally, Friedman et al. (2009) in a further
analysis of the STAR*D data, found that those with chronic depression were often not
responsive to pharmacotherapy. For these chronically depressed patients, a switch to
Cognitive Therapy was equally effective as augmenting pharmacotherapy with Cognitive
Therapy but without any worrisome side effects that are inherent with psychiatric
medications. Lengthier remission/recovery periods and lower recurrence/relapse rates
may enhance the cost effectiveness of psychotherapeutic interventions when calculated
over longer time spans (Dobson et al., 2008). Thus, exploring psychotherapeutic
interventions may be useful in reducing remission rates for depression, especially
amongst the chronically depressed.
Cognitive Behavioral Therapy
CBT has been shown to be effective in the treatment of depression in more
randomized controlled trials than any other psychosocial treatment (Persons, Davidson, &
Tompkins, 2001) and, as stated above, has the potential to increase positive long-term
outcomes. However, a review of meta-analyses for depression yields mixed results
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(Beutler, Castonguay, & Follette, 2006). In general, it has been found that CBT is more
effective than waitlist and placebo, and marginally more effective than other bona fide
psychotherapeutic interventions (Dobson, 1989; Gloaguen, Cottraux, Cucherat, &
Blackburn, 1998). The Treatment of Depression Collaborative Research Project
(TDCRP) found CBT to be an effective treatment for mild to moderate depression but
recommended medication management for those suffering from more severe depression
(Elkin et al., 1989). However, more recent studies have shown CBT to be equally
effective as medication for moderate to severe depression (DeRubeis et al., 2005). One
strength of CBT is that its effects appear to be maintained after treatment is discontinued,
with maintenance effects that compare favorably to ongoing antidepressant treatment
(Hollon et al., 2005).
CBT is a result of a merger of cognitive psychology based on the practice and
research of Aaron T. Beck (1976) and behavior therapy. Beck proposed that depressive
symptoms result when stressful external life events activate maladaptive schema or
cognitive structures that bias the interpretation of experiences (Beck, Rush, Shaw, &
Emery, 1979). These maladaptive schemas influence overt behaviors, cognitions or
automatic thoughts, and emotions. The interactions among these elements are believed to
be reciprocal and causal in nature, with a change in one affecting the others. In the
context of a structured therapy session, CBT uses several interventions that are aimed at
changing maladaptive schemas that influence overt behaviors, cognitions or automatic
thoughts, and emotions in combination with behaviorally based treatment objectives
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aimed at increasing contact with naturally reinforcing contingencies through goal setting
and homework assignments.
However, a component analysis by Jacobsen et al. (1996) found that Behavior
Activation (BA) alone is equal in efficacy to a full CBT package suggesting that the
Cognitive Therapy (CT) component may not have incremental validity or be a necessary
component of treatment for adults. Time-course investigations have revealed a
significant amount of the change in CBT occurs within the first four weeks of treatment
(Ilardi & Craighead, 1994) and these rapid responders tend to experience superior
outcome regardless of treatment condition (Busch, Kanter, Landes, & Kohlenberg, 2006;
Renaud et al., 1998). Further, the National Institute of Mental Health sponsored
Treatment of Depression Collaborative Research Project (Elkin, 1994) demonstrated a
similarity in outcome for CBT patients that did not experience a sudden gain and those
that received placebo plus clinical management. This suggests that positive treatment
effects in CBT treatment may hinge on the presence of this sudden gain and draw the
mechanisms of action further into question.
Behavior Therapy
There is solid empirical support for using a purely behavioral model among
depressed adults (Jacobsen et al., 1996) and among older adults (Scogin, Jamison, &
Gochneaur, 1989). Dimidjian et al. (2006) found BA to be as effective as antidepressant
medications and superior to CT in acute treatment of moderately to severely depressed
adults. Further support comes from the relatively weak evidence for the proposed
mechanisms of action in CT as well as findings from a component analysis by Jacobsen
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et al. (1996) demonstrating the purely behavioral component of CBT is equal in efficacy
to a full CT package. This suggests that the CT component may not have incremental
validity or be a necessary component of treatment for adults.
Jacobsen describes BA as “the application of behavioral principles such as goal
setting, self-monitoring, activity scheduling, problem solving, and graded task
assignment” to alter the avoidance and ruminative behaviors that are characteristic of
depression. Furthermore, BA seeks to increase behaviors that put the participant in
contact with natural reinforcing contingencies that will ultimately become selfmaintained and to decrease activities that promote depressive symptomology. This is
accomplished by performing an ideographic functional analysis to identify problematic
avoidance behavior and alternative coping strategies to produce higher rates of
meaningful response contingent positive reinforcement (Kanter, Mulick, Busch, Berlin,
& Martell, 2007). Once identified, these maladaptive avoidance behaviors are then
targeted for extinction and activities that are naturally reinforcing, sustainable, and
adaptive for each individual are promoted through guided scheduling of these activities.
BA seeks to increase these alternative behaviors though the assignment of homework to
help lift dysphoric mood. This process focuses on a functional-experimental approach
where a participant is encouraged to evaluate how behavior is serving them and making a
choice to avoid or activate based on experience. If they chose to “activate” a new coping
behavior, they are encouraged to evaluate the outcome with the hope that adaptive
behaviors will be maintained post-intervention. The explicit goal of BA is to increase
RCPR in order to facilitate long-term improvement in mood. Kanter, Baruch, and
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Gaynor (2006) have suggested that taking such an approach might lead clients to better
understand and manipulate the antecedent and consequential stimuli that control behavior
and thus develop more accurate and effective rules facilitating treatment gains.
Acceptance and Commitment Therapy
Another promising behavioral treatment for depression is Acceptance and
Commitment Therapy (ACT) (Hayes et al., 1999). ACT is behavior therapy that has
recently shown promise in areas including psychopathology (anxiety, psychosis, PTSD,
trichotillomania), stress, pain, job performance and negative affectivity (Hayes, Luoma,
Bond, Masuda, & Lillis, 2006). An early version of ACT individual therapy with
depressed adult women demonstrated that participants were significantly less depressed
at follow-up compared to a group assigned to CT (Zettle & Hayes, 1986). ACT has also
shown promise as a group intervention for depressed adults (Zettle & Rains, 1989).
It has been suggested that the role of verbal behavior and psychological
inflexibility may be one reason that some people are resistant to BA. In fact, it has been
suggested that the theoretical choice point between the use of BA and ACT may lie in the
extent to which verbal processes are influencing maladaptive behaviors, with ACT
potentially being the treatment of choice for clients with an over-expansive, rigid verbal
repertoire (Kanter et al., 2006). Theoretical support for many of the basic ACT processes
that seek to alter ineffective verbal control and avoidance strategies is described by
growing research in Relational Frame Theory (RFT; Hayes et al., 2001). ACT suggests
weak or ineffective contextual control of language (faulty/rigid verbal rules) produces
psychological inflexibility that limits the contact with direct contingencies and is the root
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of psychopathology. Consistent with this possibility is the fact that clients whom endorse
more reasons (verbal rules) for depression tended to have poorer outcomes in BA (Addis,
Truax, & Jacobsen, 1996). ACT seeks to alter the functions of private events through
“cognitive defusion,” a process that decreases the believability of private events, which in
turn decreases psychological rigidity regarding the private experience. Additionally,
ACT seeks to create psychological flexibility through acceptance/willingness and
mindfulness of private events as a form of exposure to previously avoided contexts and
sensations. BA does not have an explicit strategy to deal with this entrenched
experiential avoidance or rigid verbal control. The final part of the ACT model is to assist
the client to choose values of personal importance and take committed action in the
direction of those values (Hayes et al., 2006), which is functionally similar to Behavior
Activation. ACT attempts create psychological flexibility through the weakening of
verbal control thus allowing for behavioral flexibility to contact the direct contingencies
in this final phase of ACT. Differing from BA, the explicit goal of ACT is to increase
values directed behavior rather than to lift dysphoric mood, although improved mood
may be an associated consequence. It has been suggested that using ACT with treatment
resistant clients may be particularly effective.
Inpatient Care
In cases of severe depression where acute suicidality or homicidality is present,
inpatient care via voluntary or mandated commitment to a hospital setting is often
utilized. This practice currently accounts for 50 to 60% of all psychiatric hospitalizations
(Sullivan, Barren, Bezmen, Rivera, & Zapata-Vega, 2005). Inpatient care is not only the
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most restrictive form of care; it also represents the most expensive treatment available for
depression. Cotterill and Thomas (2004) found the typical cost per case in inpatient
treatment was between $5,000 and $7,000 for an average of $410–$638 per day. In
addition to these concerns are concerns of stigma, disruption of family life, as well as the
fact that those that are hospitalized may lose their jobs as a result of time missed. In
addition, those that are admitted to an inpatient unit are re-admitted at a rate of 40–60%
at one-year follow-up (Lin, Moyle, Chang, Chou, & Hsu, 2009). Thus, it is important to
identify treatments that may decrease the length of stay in an inpatient unit as well as
effectively prevent recurrence and re-hospitalization.
Treatment that is received in inpatient settings may vary greatly (Brabender,
1993), yet very few outcome studies have been conducted to evaluate short-term
treatments in these settings (Jarrett, 1995). Given the expense and personal cost in time
and freedom to an individual that has been hospitalized, briefer and more effective
treatments are always being sought. This is especially important considering that
depressive symptom severity at discharge is associated with risk of future hospitalization
(Lieberman, Wiitala, Elliott, McCormick, & Goyette, 1998).
Currently, antidepressant medications are the “mainstay” in treatment with
suicidal patients with acute, recurrent or chronic depression. However, there is little
evidence to suggest that antidepressants reduce suicide risk (APA, 2000b). In fact, there
is some evidence that antidepressants may increase suicidality. An increased risk for
completed suicide of about twice that of the base rate for an at-risk population was found
in the first 12 weeks following the beginning of antidepressant treatment (Valenstein
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et al., 2009). These concerns necessitate further research into brief inpatient
interventions. Additionally, a large proportion of patients with Major Depressive
Disorder suffer a chronic (25%) or recurrent (75%) course (Rush et al., 2008), and there
is no evidence that antidepressants alter the course of depression (Dimidjian et al., 2006).
Since antidepressants do not appear to have enduring effects after use is discontinued,
patients may be at significant risk for relapse and recurrence (Hollon, Thase, &
Markowitz, 2002). The current recommendation for the treatment of chronic or recurrent
episodes of depression is prescription of antidepressants indefinitely (American
Psychiatric Association, 2000). Given that some psychotherapeutic interventions have
been proven to have enduring effects and to be equally efficacious for the treatment of
depression in adults as medication (Dimidjian et al., 2006), using psychotherapy for
treatment of depression with antidepressants in adjunct or in response to a lack of
improvement or relapse may provide significant long-term savings (Broten, Naugle,
Kalata, & Gaynor, 2011).
Inpatient Treatments
Given the relative lack of empirical investigation into the effectiveness of brief
inpatient treatments, it is logical to attempt to modify current empirically support
treatments as previously described for this purpose. Hopko and colleagues have
conducted one such investigation. The Brief Behavioral Activation Treatment for
Depression (BATD; Hopko, Lejuez, LePage, Hopko, & McNeil, 2003; Lejuez, Hopko, &
Hopko, 2001, 2002; Lejuez, Hopko, LePage, Hopko, & McNeil, 2001) is based on the
Behavioral Activation treatment that has previously been demonstrated to be effective

18
with severely depressed individuals (Dimidjian et al., 2006). BATD provides a brief,
manualized approach for intervention in a hospital setting. In a small trial, BATD plus
antidepressant medication when compared to supportive treatment as usual plus
antidepressant medication achieved favorable outcome with a large effect size of .73 after
only a 2-week treatment period (Hopko et al., 2003).
However, given the limitations of BA as previously described, ACT may be may
be a more appropriate intervention for inpatient treatment of depression. Given the fact
that a high percentage of patients that have been hospitalized were admitted due to acute
suicidality, it can be reasoned that they most likely have high levels of cognitive fusion,
which is explicitly targeted by ACT. Additionally, since hospitalization is the most
restrictive and expensive option in the treatment of depression (Broten et al., 2011), it is
likely that many other approaches may have been implemented before this step that have
not been effective for the patient. As stated above, the ACT model may be of particular
utility for treatment resistant psychopathology (Kanter et al., 2006). There is also recent
empirical support for brief ACT interventions in inpatient settings. Other research (Bach
& Hayes 2002; Bach, Hayes, & Gallop, 2012; Gaudinano & Herbert, 2006) found that
four sessions of ACT + treatment as usual was found to greatly decrease the number of
patients re-admitted to an inpatient unit for psychosis over the following 3-month time
period when compared to treatment as usual alone. In addition, ACT has been found to
be an effective treatment for co-morbid depression and substance abuse in an inpatient
setting (Petersen & Zettle, 2009). Since co-morbidity in severely depressed populations
is the rule rather than the exception, ACT may be an appropriate intervention.
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Statement of Purpose
The present study sought to investigate the utility of a brief Acceptance and
Commitment Therapy protocol for the treatment of depression in an inpatient setting.
ACT is a generally promising treatment for a variety of psychological issues. Given the
positive, albeit modest, results in its use with adult depression, further evaluation is
necessary. Participants were randomly assigned using and weighted, blocked distribution
to either Treatment as Usual (TAU) or individual sessions of ACT in conjunction with
treatment as usual (ACT). The study compared re-admission rates between the ACT
intervention group and the TAU group at 3 months and 6 months. In addition, the study
examined the proposed mechanisms of change and depression rates between groups.

CHAPTER II
METHOD
Participants
Forty-six adults were recruited form Borgess Medical Center’s adult inpatient
mood disorder unit that were experiencing primary depressive type symptoms. These
participants were recruited without regard to race, sex, socioeconomic status, or ethnicity.
Participants were initially informed of the study by inpatient unit intake personnel, social
workers, or nursing staff who read a script detailing the study to the patient. Often
patients entered the hospital after a crisis situation such as a suicide attempt, self-injury,
or self-admittance to an emergency room. Recruitment took place as soon as the patient
had been admitted to the inpatient unit and was deemed stable enough based on the
clinical judgment of the Borgess clinical staff to understand the nature of the study. The
hospital staff contacted the researcher if the patient was interested in hearing more about
the study. A meeting time was then established between the hospital staff and the
researcher to provide more information regarding potential participation with the
possibility to consent for those interested in participating based on room and participant
availability.
Inclusion/Exclusion Criteria
All participants that were admitted to the inpatient mood disorder unit were
eligible to participate in the study with the following exclusionary criteria: primary
diagnosis of a non-depressive disorder such as a formal diagnosis of mental retardation or
20
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autism spectrum disorder on Axis I of the Diagnostic and Statistical Manual of Mental
Disorders (American Psychiatric Association, 1994), severe obsessive-compulsive
disorder, panic disorder, and schizophrenia spectrum disorders. Finally, those who are
non-English speaking or whose primary residence is outside of the area covered within
the SolCom computer system database would be excluded.
Setting
Initial assessment sessions and post-treatment assessment sessions, and all
treatment sessions took place in the inpatient mood disorder unit of Borgess Medical
Center in a private room by the Student Investigator, Lucas Broten. The electronic
medical record was examined by the researcher and was used to conduct the
exclusion/inclusion analysis. Phone-based follow-up assessment sessions were
conducted either at Borgess Medical Center in a private room or in the laboratory of Dr.
Scott Gaynor at Western Michigan University by Lucas Broten or by a trained and
Human Subjects Institutional Review Board (HSIRB) approved doctoral student from the
clinical psychology program. All information gathered outside of the laboratory of Dr.
Scott Gaynor was transported to the aforementioned lab in a locked briefcase until it was
stored in the locked laboratory and cabinet at Western Michigan University.
Materials
The Montgomery Åsberg Depression Rating Scale (MADRS; Montgomery &
Åsberg, 1979) is a widely used clinician administered rating scale for depression used to
measure overall severity of depression. It consists of 10 items that are rated on a 0-6
Likert-type scale and is based on functioning over the previous 7 days. The MADRS has
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high inter-rater correlations that have recently been shown to be excellent when used in
conjunction with the recently developed interview guide (Takahashi, Tomita, Higuchi, &
Inada, 2004; Williams & Kobak, 2008). It has good concurrent validity with other
clinical interviews for depression, such as the Hamilton Rating Scale of Depression
(Maier & Philipp, 1985). The scoring is on a 0-60 scale with higher scores indicating
more severe depressive symptomology. The typical cut-off points are 5: not at all ill; 11:
Borderline; 19: Mild; 29: Moderate; >31: Severe. The MADRS takes roughly 15 minutes
to administer. Additionally, the MADRS has been shown to be equally effective when
administered by telephone as when administered face-to-face (Kobak, Williams, Jeglic,
Salvucci, & Sharp, 2008).
Acceptance and Commitment Therapy Hexaflex Diagnostic and Assessment–
Revised (Wilson & Groom, 2002) is a measure of each of the core processes of the ACT
theoretical model including contact with the present moment, acceptance, values,
defusion, self as context, and committed action. This was adapted by the researchers to
include a quality and engagement metric that was rated at the end of each session. A 0-6
rating scale was used. This was a therapist report measure and was based on the
therapist’s opinion of the level of participant contact with the ACT processes. Points
were assigned based on therapist checks of understanding and therapist opinion of
engagement for each of the relevant ACT processes. A 6 rating would represent that the
session was of superior quality and engagement, while a 0 would indicate a lack of
understanding for all aspects of the session or complete disengagement (such as
sleeping).
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Demographic Information Collection Sheet (see Appendix C) was created
especially for this research study to track the demographics of subjects. This was used to
help ensure that the groups were distributed equally and that randomization has occurred.
Information on this sheet was gathered from the electronic medical record with the
knowledge and consent of the participants.
Beck Depression Inventory–II (BDI-II) (Beck, Steer, & Brown, 1996) is a widely
used 21-item self-report instrument administered at pre- and post-treatment and followup. Items are scored on a 4-point Likert scale with item-specific content defining each
point (where 0 = no endorsement of the symptom, and 3 = extreme endorsement),
resulting in total scores ranging from 0 (not at all depressed) to 63 (extremely depressed).
Items assess various emotional, cognitive, and overt behavioral aspects of depression
(e.g., “sadness,” “pessimism,” and “changes in sleeping pattern”). Elevated BDI-II scores
correlate well with diagnoses of depression achieved with the Structured Clinical
Interview for DSM-IV Axis I Disorders (SCID-I; First, Spitzer, Gibbon, & Williams,
1995), with mean scores of 18 indicating mild Major Depressive Episodes, mean scores
of 27 indicating a moderate Major Depressive Episodes, and mean scores of 34 indicating
a severe Major Depressive Episodes with 99% accuracy (Steer, Brown, Beck, &
Sanderson, 2001). Additionally, the instrument has a test-retest reliability of between .93
and .96 (see Beck et al., 1996).
Acceptance and Action Questionnaire–II (AAQ-II) (Bond et al., 2011) is a selfreport measure of assesses the construct referred to as, variously, acceptance, experiential
avoidance, and psychological inflexibility. Results from 2,816 participants across six

24
samples indicate the satisfactory structure, reliability, and validity of this measure. The
mean alpha coefficient is .84 (.78 – .88), and the 3- and 12-month test-retest reliability is
.81 and .79, respectively. Results indicate that AAQ-II scores concurrently,
longitudinally, and incrementally predict a range of outcomes, from mental health to
work absence rates, which are consistent with its underlying theory. The AAQ-II also
demonstrates appropriate discriminant validity. The AAQ-II appears to measure the same
concept as the AAQ-I (r = .97), but with better psychometric consistency. Consistent
with the theory underlying acceptance and commitment therapy (ACT), items converged
into a 7-item scale.
Environment Reward Observation System (EROS) (Armento & Hopko, 2007) is a
10-item questionnaire designed to measure response-contingent positive reinforcement.
Responses are rated on a 4-point Likert scale (1 = strongly disagree, to 4 = strongly
agree). This measure has demonstrated strong internal consistency, test-retest reliability,
and convergent, discriminate, and ecological validity. The scale has been developed
using college student samples; however, more recent work has been done with adult
depressed populations. Armento and Hopko found that changes EROS scores
significantly predicted time spent in low and high reward value behaviors above and
beyond depression scores alone. Given that ACT specifically attempts to increase valued
behavior, this measure was selected to sample these changes.
Automatic Thoughts Questionnaire–Frequency and Believability (ATQ-B) (Addis
et al., 1996 is a 30-item self-report measure that assesses separately the frequency and
believability of automatic negative self-thoughts associated with depression. The ATQ
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(Hollon & Kendall, 1980) has typically been used to investigate the efficacy of cognitive
therapy in depression research. Addis, Truax, and Jacobson revised this measure to add a
believability component, which is now commonly used as a measure of cognitive
defusion in ACT research. Responses to items range on a 5-point Likert scale from 1
(never) to 5 (always) with higher scores indicating increasing severity on both the
believability and frequency measures. Normative samples indicate a frequency scale
mean of 52.91 (SD = 18.18) (Dozois, 2003).
Inventory of Interpersonal Problems–Personality Disorders–25 (IIP-PD; Kim &
Pilkonis, 1999) is a 25-item self-report scale that screens for personality
disorders. Responders rate each item on a 5-point Likert scale. The items on the measure
compose five scales: Interpersonal Sensitivity, Interpersonal Ambivalence, Aggression,
Need for Social Approval, and Lack of Sociability. Subscale scores are calculated by
obtaining the mean of the items that comprise the subscale. Of these subscales, the mean
scores of the Interpersonal Sensitivity, Interpersonal Ambivalence, and Aggression can
be used to screen for personality disorders. The authors suggest that a PD index score of
.7 – 1.1 indicate a possible personality disorder, and a score above 1.1 indicates that a
personality disorder is probably present. In a clinical sample (N = 1149), the IIP-PD was
administered along with a diagnostic personality disorders interview, the items that would
later comprise the IIP-PD-25 were then investigated. The five subscales and a high
internal consistency α = .8, additionally there was strong agreement with subscale scores
from the IIP-PD with Pearson product-moment correlations ranging from .92 – .97. The
IIP-PD was administered at pre-treatment assessment sessions.
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Design
A randomized controlled trial was utilized in which each participant was
randomly assigned to either Treatment As Usual (TAU) or treatment as usual with the
addition of individual sessions of Acceptance and Commitment Therapy (referred to as
ACT from here forward). Random assignment to the groups took place at a ratio of 2 to
1 in favor of TAU, that is, for each participant assigned to ACT, two were assigned to
TAU. Each participant was assigned an identification number upon consenting to the
study according to the order in which they joined. Using a computer-generated
randomizer, the numbers were pre-assigned to either the TAU or ACT in blocks of 3
stratified by gender. Based on gender, each participant was given a number in blocks of
3 and was randomly assigned (2 to TAU and 1 to ACT) to ensure equal gender
distribution for the duration of the study. This assignment was indicated in a sealed
envelope that was not opened until after the consent process and prior to implementation
of any interventions to prevent researcher bias. The purpose of the weighted assignment
was to allow for the highest number of participants to be included in the study while
maintaining a feasible number of participants for the researcher to conduct the ACT
sessions given the limited time and space for these sessions.
Data regarding re-hospitalization were collected at 3 months after discharge using
the SolCom computer system. The SolCom system tracks all hospital admissions
(including emergency room visits) in the Borgess Medical Center system, which is the
primary mental health crisis center in the region. Therefore, if a mental health
hospitalization were to occur, provided the participant stayed in the area, it would likely
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be documented in this database. If re-hospitalization or an ER visit occurred, it was
measured from day of release from the index hospitalization at Borgess Medical Center
during which the treatment took place to the first day of re-hospitalization subsequent to
their release within the 3-month follow-up.
Length of stay was calculated as the number of days of hospitalization in which
the participant consented to the study. This was measured from admittance to discharge.
The baseline days preceding the index hospitalization was collected in the same
manner, except records of hospitalizations in the year prior to the index hospitalization
were examined. Baseline days to hospitalization were measured as the number of
retrospective days from the first day of the index hospitalization to the previous
hospitalization, up to 1 year. The purpose of these data is to allow for a comparison of the
frequency, duration, and number of hospitalizations prior to and after the index
hospitalization. Thus, the time to and in between hospitalizations and the duration of
each hospitalization were documented.
Conditions
TAU. TAU on the inpatient unit generally consisted of medication, attendance of
up to three 45-minute psychoeducational groups per day, and one 75-minute group
therapy session per day. Each patient also received case management services (including
relevant referrals upon discharge), individual meetings and therapy sessions with these
case managers, and consultation with a psychiatrist on a minimum of a weekly basis.
The program was generally Cognitive Behavior Therapy oriented. This is partially
apparent in the topics of psychoeducational groups, which typically focused on
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interpersonal difficulties, recognition and challenging of maladaptive thoughts,
anger/anxiety management, and conflict resolution. Group therapy sessions typically
focused on discussing and “processing” the experience that brought them to the hospital.
ACT. ACT is based on a model of psychopathology that has at its core the
construct of psychological inflexibility. Psychological inflexibility is exemplified when
an individual’s behavior is directed at attempts to avoid or escape private events, in a way
that significantly limits or restricts behavior directed towards important life domains. For
instance, a depressed individual may be preoccupied with terminating negative selfthoughts, guilt, and painful attributions. This experiential avoidance may be codified into
rules—“I shouldn’t feel like this, I can’t stand this, If only I felt/thought better I
could…”— that inhibit adaptive behavior (e.g., attending a social function, seeing one’s
children) or promote avoidance/escape (e.g., oversleeping or overeating).
An ACT approach emphasizes increasing psychological flexibility through an
integrated combination of acceptance-based practices to address how the individual
relates to and experiences private events and behavior change strategies to increase goaldirected, values-based activity.
ACT Intervention
The following is meant to give a general description of the treatment. A more
thorough description of the treatment protocol is included in Appendix A. Participants
may or may not have received the entire treatment package based on the length of the
hospital stay. Each therapy session was specifically designed to “stand alone,” that is,
provide a therapeutic benefit without relying on future sessions.
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Participants that were randomized to ACT received an initial assessment, which
included the MADRS, BDI-II, ATQ-B, AAQ-II, EROS, IIP, Demographic Questionnaire,
and Baseline Hospitalization information. This was followed immediately by the first
ACT session. The assessment period typically took approximately 50 minutes. All
treatment sessions varied in length based on availability, engagement, and willingness to
participate. Sessions length was recorded in minutes to ensure that treatment time was
consistent for analysis. The ACT sessions were arranged at the end of the day to ensure
there was no interference with TAU. The session took place after all other therapy
sessions were concluded and was conducted around scheduled personal visits and dinner
at the convenience of the participant.
The first session took place as soon as possible after Assessment #1. This session
consisted of consent to participate and was followed by intake measures and the first
session of ACT material. Due to the variable duration of the length of stay, each ACT
session was a self-contained session. That is, each had a primary focus but incorporated
multiple aspects of ACT. The focus of the first session was primarily oriented to getting
an overview of the patient’s personal struggle with depression, obtaining the baseline
measure for the ACT daily dairy card, rapport building and “creative hopelessness.”
Creative hopelessness is an ACT intervention that focuses on challenging the normal
agenda that the patient has been using to interact with his or her environment. The goal is
to demonstrate that the problem is not that the patient is not trying hard enough; it is that
something new needs to be done. This is fostered through metaphor and experiential
exercises. Finally, values were introduced and the bull’s eye was assigned as homework.
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The therapist filled out the Hexaflex Diagnostic and Assessment–Revised as a measure of
quality and engagement in the session and noted the length of the session.
The second session took place within 72 hours of the first. It began with filling
out the ACT daily dairy card and reviewing the homework. The session focus was on
identifying areas where attempts to control internal experiences were actually the
problem. This was discussed in the context of how thoughts and feelings can prevent
living a valued life. Finally, one small values consistent goal was assigned as homework.
The therapist filled out the Hexaflex Diagnostic and Assessment–Revised and noted the
length of the session.
The third session took place within 72 hours of the last and began by reviewing
the homework and filling out the ACT daily dairy card. The objective of the session was
to draw upon the client’s experience to strengthen the recognition that control is the
problem through defusion exercises. The patient was assigned a behavioral goal related
to an uncomfortable emotion as homework as well as carrying thoughts on cards. The
therapist filled out the Hexaflex Diagnostic and Assessment–Revised and noted the
length of the session.
The fourth session took place within 72 hours of the last and began by reviewing
the homework and filling out the ACT daily dairy card. This session focused on defusion
and the introduction of mindfulness in order to foster a sense of self as context. Part of
this session included an in-vivo exercise practicing executing a valued activity in the face
of unwanted thoughts and feelings in an adaptation of the “take your mind for a walk”
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exercise (Hayes et al., 1999). The therapist filled out the Hexaflex Diagnostic and
Assessment–Revised and noted the length of the session.
The fifth session began by reviewing the homework and filling out the ACT daily
dairy card. The objective of the session was to explore the relationship between goals and
actions, and to firmly root the components of defusion and willingness in the service of
valued actions. The session also included a discussion of how to deal with barriers that
may be encountered upon discharge. The patient was asked to record future goals
including short- and long-term plans. The therapist filled out the Hexaflex Diagnostic and
Assessment–Revised and noted the length of the session.
All participants received the assessment battery after the fifth ACT session or just
prior to discharge if five ACT sessions could not be completed before discharge. This
assessment included the MADRS, BDI-II, ATQ-B, AAQ-II, EROS, and ACT diary card.
The Length of Stay and dose of ACT sessions (in minutes) was recorded.
Additional sessions took place as frequently as possible for patients that remained
admitted to the hospital after completion of the fifth session. The focus was to emphasize
specific components of ACT that may address particular issues for each individual
patient. These sessions began by reviewing progress and difficulties and filling out the
ACT daily dairy card. Homework continued to focus on values-based behavior
assignments, and each session ended with the therapist filling out the Hexaflex
Diagnostic and Assessment–Revised and noting the length of the session (Table 1).
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Table 1
ACT Inpatient Sequence
Session

Focus

Assessments and Emphasis

1

Assessment # 1

MADRS, BDI-II, ATQ-B, AAQ-II, EROS, Demographic
info, Baseline hospitalization info

1

ACT # 1

Creative Hopelessness/Values

2

ACT # 2

Defusion/Values

3

ACT # 3

Defusion/Values

4

ACT # 4

Defusion/Self as Context/Mindfulness/Values

5

ACT # 5

Willingness/Barriers/Values

5

Assessment # 2

MADRS, BDI-II, ATQ-B, AAQ-II, EROS, Length of Stay,
Treatment Receipt Measure

6 and beyond
(if necessary)

ACT Booster
Sessions

Variable ACT strategies

Variable

Assessment # 3
(if the patient
remains
hospitalized)

MADRS, BDI-II, ATQ-B, AAQ-II, EROS, Length of Stay,
Treatment Receipt Measure

Treatment as Usual Intervention
Participants that were randomized to TAU received an initial assessment, which
included the MADRS, BDI-II, ATQ-B, AAQ-II, EROS, IIP, Demographic Questionnaire,
and Baseline Hospitalization information. This was followed by an assessment prior to
release, which consisted of MADRS, BDI-II, ATQ-B, AAQ-II, EROS, and the Length of
Stay (Table 2).
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Table 2
TAU Inpatient Sequence
Session

Focus

Assessments and Emphasis

1

Assessment # 1

MADRS, BDI-II, ATQ-B, AAQ-II, EROS, IIP,
Demographic Questionnaire, Baseline
Hospitalization information

2

Assessment # 2

MADRS, BDI-II, ATQ-B, AAQ-II, EROS, Length
of Stay, Treatment Receipt Measure

Follow-up
All participants were asked to meet with the researcher for follow-up interviews at
3- and 6-months post-treatment. These interviews consisted of MADRS, BDI-II, ATQB, AAQ-II, EROS, and data on re-hospitalization were collected from the SolCom
electronic medical record system (Table 3). In cases where the patient could not be
present for the follow-up assessment sessions, they were contacted and asked to complete
the measures by phone.

Table 3
Follow-up Assessment Sequence for All Participants
Session

Assessment

3 month

MADRS, BDI-II, ATQ-B, AAQ-II, EROS, Re-hospitalization

6 month

MADRS, BDI-II, ATQ-B, AAQ-II, EROS, Re-hospitalization
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Human Subjects Protection
Prior to any treatment, each prospective participant had an informed consent
document (Appendix B) read aloud to him or her by a doctoral student from Western
Michigan University. Should the prospective participant agree to participate in the study,
he or she was asked to sign two copies of the informed consent document. One copy was
retained in his or her file at Western Michigan University and the other copy was placed
in the participant’s file to be given to the participant for his or her records. The informed
consent document included information about the procedures used, the time commitment
involved, potential risks, potential benefits, confidentiality, and protections for
participants involved in the study. This document was made available to the participant
at any time during the course of the inpatient treatment upon request. The informed
consent documents also notified the participant that he or she has the right to discontinue
his or her participation in the study at any time without prejudice or penalty. Finally, the
informed consent documents included the names and phone numbers of the principal and
student investigator, in addition to the phone numbers for the Chair of the Human
Subjects Institutional Review Board and for the Vice President of Research as well as the
phone numbers of the Borgess IRB Chair, and informed the subject that he or she could
contact any of these individuals during the course of the study should any questions or
concerns about the study arise.

CHAPTER IV
RESULTS
Participants
Forty-six inpatients at Borgess Medical Center who were experiencing primary
depressive symptoms at the time of admission agreed to attend an informed consent
session to hear more about potential study participation. Of these 46, 7 declined to
participate after hearing a more thorough description of the study, leaving 39 remaining
participants that were randomized. Given the 2 to 1 ratio for randomization in favor of
TAU to ACT, 25 participants were randomized to TAU and 14 to ACT. Everyone who
was randomized received at least one day of treatment. Everyone in both samples
received a post-treatment assessment with the exception of one participant in the TAU
group, who was released early and was unreachable at the contact information that was
provided (disconnected phone).
All participants from both groups were available for electronic medical record
review for all initial, post, and follow-up assessments. In the ACT group, all participants
completed all measures for initial and post-treatment self-report measures. For the TAU
group, 24 were analyzed for interview and self-report measures with the exception of the
BDI-II, for which responses for 23 participants were available for analysis. The small
amount of missing data was due to a failure to complete these measures (see Figure 1).
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Figure 1. Enrollment flowchart.

Characteristics of the Sample
Across measures of demographics, no significant differences were found between
the experimental (ACT) group and the control (TAU) group with the exception of age
(see Table 4). The ACT group was statistically significantly older on average than the
TAU group (47.9 years vs. 39.4 years, respectively). There were no significant
differences in gender, number of children, racial/ethnic status, income, relationship
status, occupational status, or education.
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Table 4
Demographic Characteristics of Participants in the ACT and TAU Conditions
Variable

Total
(n=39)

ACT
(n=14)

TAU
(n=25)

Gender
Male
Female

41%
59%

43%
57%

40%
60%

Average Age
Age

42.41 (11.49)

47.85 (10.78)

39.36 (10.91)

Children
Yes
No
Ethnicity
Caucasian
African American
Hispanic/Latino
Multiracial
Household Income (n=38)
$0-19,999
$20,000-34,999
> $35,000
Marital Status
Single
Married
Domestic partnership
Separated
Widowed
Divorced
Occupational Status
Employed
Retired
Unemployed
On disability
Stay at home parent
Education
Did not graduate HS
GED
Graduated HS
Some college
2-year college degree
4-year college degree
Graduate degree

Test/p-Value

2; p= .86

F=5.489; p=.03*

2; p=.73
46%
54%

43%
57%

48%
52%

2; p=.21
74.4%
17.9%
2.6%
5.1%

64%
29%
7%
0%

80%
12%
0%
8%

2; p=.60
63%
24%
13%

57%
14%
29%

66%
13%
21%

2; p=.15
28%
23%
8%
5%
13%
23%

14%
42%
14%
0%
7%
21%

36%
12%
4%
8%
16%
24%

2; p=.17
29%
16%
31.8%
15.8%
2.6%

31%
20%
31%
12%
8%

28%
8%
32%
23%
0%

2; p=.48
7.7%
12.8%
12.8%
28.2%
15.4%
12.8%
10.3%

* Statistically significant difference

7%
29%
21.5%
21.5%
7%
14%
0%

8%
4%
8%
32%
20%
12%
16%
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The sample was also compared on clinical characteristics assessed prior to the
initial session. Across measures, no significant differences were found between the
experimental (ACT) group and the control (TAU) group. Specifically, there were no
significant differences on the MADRS interview, the BDI-II, ATQ-B, AAQ-II, or the
EROS. The sample was significantly elevated on all measures compared to normative
samples and comparable to previous depressed inpatient samples. Pre-intervention
MADRS scores had a mean of 43.1, which is two standard deviations greater than a
depressed outpatient sample from the literature (20.5; Williams & Kobak, 2008). The
pre-intervention BDI score mean was 36.8, which is similar to previous studies with a
depressed geriatric inpatient sample (32.69; Steer et al., 2001). The ATQ-B preintervention score had a mean of 100.3, which is equivalent to previous studies with a
depressed outpatient sample (100.26; Zettle, Rains, & Hayes, 2011). The AAQ preintervention score had a mean of 33.3, which is equivalent to previous studies with a
substance abusing inpatient sample (33.34; Bond et al. 2011). The EROS preintervention score had a mean of 19.2, which is more than two standard deviations lower
(indicating less contact with reinforcement) than the mean score obtained in a sample of
non-depressed college students (29.46; Armento & Hopko, 2007).
All participants had a hospital physician assigned DSM-IV depressive disorder
diagnosis. In addition, high co-morbidity with other mental and physical health diagnoses
was apparent. When considering the total sample, 61% had multiple Axis I diagnoses
from the DSM-IV, one of which was depression related as required for participation.
Eighteen percent of the total had a diagnosed Axis II disorder. However, when examined
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using the IIP, the percentage with a likely personality disorder increased. The IIP uses a
cut score of 1.1 to determine the likely presence of a personality disorder. When this
score was used, 72% of the total (n = 32) were indicated as probably having a personality
disorder. This was evenly distributed across groups (73% of ACT vs. 71% of TAU,
respectively, p = .94). Additionally, 51% of the sample had a diagnosis on Axis III as
well. The sample clearly was experiencing significant depressive symptoms and a range
of co-morbidities consistent with previous depressed inpatient samples (see Table 5).
Correlations between the primary measure of depressive symptoms, the MADRS,
and other measures of symptomology were examined. These are presented in Table 6.
These correlations are as expected, with relatively high positive correlations
between measures of depression (BDI), psychological inflexibility (AAQ-II), and
frequency and believability of negative self thoughts (ATQ-F/B). There was a negative
correlation between response contingent reward (EROS), which would be predicted in a
highly depressed population.
Re-hospitalization Data
The primary (and most objective) measure of outcome was re-hospitalization
data. The data in the present report consist of data collected from the previously
described SolCom system records regarding re-hospitalization. Patient data that were
part of the SolCom system during the previous year and subsequent 6 months from the
index hospitalization were used in the analyses.
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Table 5
Clinical Characteristics of Participants in the ACT and TAU Conditions
Measure

Total (n=39)

ACT (n=14)

TAU (n=25)

Statistic

MADRS

43.10 (9.16)

43.86 (9.30)

42.68 (9.25)

F=.15; p=.71

BDI - II

36.81 (12.46)

36.15 (10.57)

37.16 (13.57)

F=.05; p=.82

AAQ

33.3 (11.09)

33.21 (9.15)

33.42 (12.27)

F=.00; p=.96

ATQ-B

100.26 (31.21)

103.14 (28.18)

98.58 (33.32)

F=.19; p=.67

ATQ-F

108.4 (32.20)

106.00 (28.40)

109.83 (34.74)

F=1.22; p=.73

EROS

19.2 (6.50)

17.83 (6.26)

19.88 (6.62)

F=.80; p=.38

Personality
Assessment

Total (n=32)

ACT (n=11)

TAU (n=21)

Statistic

IIP

1.69(.82)

1.48(.53)

1.79(.93)

F=1.05; p=.31

Met or exceed
IIP cut score

72%

73%

71%

p = .938

Diagnostic Data

Total
(n=31)

ACT
(n=9)

TAU
(n=25)

Statistic

Axis I
MDD

68%

77%

52%

2; p=.429

Anxiety

19%

22%

16%

2; p=.067

Bipolar

32%

22%

32%

2; p=.228

Substance
Abuse

16%

22%

12%

2; p=.348

PTSD

13%

11%

12%

2; p=.236

Dysthymia

3%

0%

4%

2; p=.423

Postpartum
Depression

3%

11%

0%

2; p=.290

Alcohol
Dependence

3%

11%

0%

2; p=.290

Mood Disorder

6%

0%

8%

2; p=.429

Gender Identity

3%

11%

0%

2; p=.290

Acute Stress

3%

0%

4%

2; p=.423

Multiple Axis I

61%

67%

50%

2; p=.418

Axis II

18%

8%

25%

2; p=.673

Axis III

51%

36%

61%

2; p=.364
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Table 6
Correlation Matrix for Outcome Measures at Index
Measure

Correlation Coefficient with the MARDS

BDI

.73

AAQ-II

.69

ATQ-F

.69

ATQ-B

.87

EROS

–.74

Prior Hospitalization
After consent, data from 12 and 3 months prior to the index hospitalization were
recorded. Days from the index hospitalization to the most recent previous mental health
related hospital contact and inpatient admission were also recorded (see Table 7).
Among the entire sample, 21% had hospital contact in the past 3 months and 54% within
the past year, while 10% had been admitted in the past 3 months and 31% within the past
year. In the ACT and TAU groups, the percentages with hospital contact were 64% and
36%, respectively, across the prior year, and 21% and 20%, respectively, across the prior
3 months. The between-groups percentages in terms of admission were 43% and 24%
across the prior year, and 14% and 8% across the prior 3 months for the ACT and TAU
groups, respectively. For those who were hospitalized at either interval, the groups were
statistically comparable in average days from index hospitalization to any prior hospital
contact (F = 1.96, p = .201) and prior inpatient admission (F = 1.64, p = .260).
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Table 7
Average Days From Index Hospitalization
Category

Total

ACT

TAU

P-Values

Any Hospitalization in
the previous 12 months

61.82 (95.03)

88.07 (106.37)

47.12 (86.84)

F= 1.96; p=.201

Inpatient Admission in the
previous 12 months

49.72 (89.41)

71.5 (100.29)

37.52 (82.34)

F= 1.64; p=.260

Length of Index
Hospitalization

8.77 (3.80)

9.14 (3.84)

8.56 (3.84)

F= .035; p=.652

Note. Total = Total combined sample; ACT = Acceptance and Commitment Therapy; TAU = Treatment as
Usual.

Upon discharge, the length of the index hospitalization was recorded. Again, both
the ACT (9.14 days) and TAU (8.56 days) groups were statistically comparable (F= .35,
p = .784) in terms of the mean number of days in the hospital.
ACT Intervention
Given that that ACT intervention varied in length based on the patient’s length of
stay in the inpatient unit and willingness to participate, an attempt was made to quantify
the amount of engagement in the intervention. First, the number of ACT sessions and the
mean number of minutes receiving ACT were recorded. The mean minutes of therapeutic
intervention for the ACT group was 167.83 (80.25) minutes. The average number of
sessions for the ACT group was 3.67. There was a large variation in the amount of ACT
treatment received. In terms of minutes of therapeutic contact the range was from 57 to
333, and the number of sessions ranged from 1 to 6. The variability was the result of
multiple factors including length of stay, willingness of the participant to meet, and
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number of weekend days included in the stay (as ACT sessions were not delivered on the
weekend). Data were also collected on the Hexaflex Diagnostic and Assessment–
Revised, which was used as a session evaluation completed immediately following the
session by the therapist. For each area of the Hexaflex that was covered in the session, the
therapist made a rating of the extent to which the content was actively received and
engaged by the client. The average for the session provided an indicator of the quality of
ACT engagement by the participant. The average score in session quality and
engagement was 4.59 (SD = 1.62, range = 1–6).
Prior to Follow-up Hospitalization Data
Data regarding post-index hospital contact were recorded from the SolCom
system and also included a review of patient charts and cross-check of weekly admission
records. The status of each participant was recorded at 90 (3 months) and 180 days (6
months) post discharge. The status of each participant was coded as either any mental
health related hospital visit (which combines inpatient admission and ER visits), inpatient
admission, ER visit with no inpatient admission, or no contact. Since the groups were not
equivalent in size due to the weighted randomization process, the data were broken down
by percent for each group so as to provide a comparable metric to examine differences.
Each condition was compared at each time point for each criterion of interest (any
hospital contact, inpatient admission, ER, no contact). These data are summarized in
Tables 8 and 9.
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Table 8
Hospital Contact Percentage Data for ACT and TAU
Category

Any Mental
Health
Related
Visit

ER Visits

Inpatient
Admission

Hospital
visits

12 Months Prior
to Index

3 Months
Prior to Index

3 Months
Post Index

6 Months
Post Index

ACT

TAU

ACT

TAU

ACT

TAU

ACT

TAU

>0

64%

36%

21%

20%

29%

28%

50%

40%

0

36%

64%

79%

80%

71%

72%

50%

60%

1

29%

16%

14%

16%

14%

20%

21%

28%

2

21%

4%

7%

4%

7%

8%

21%

4%

3

7%

4%

0%

0%

0%

0%

0%

8%

4

7%

4%

0%

0%

7%

0%

8%

0%

5

0%

4%

0%

0%

0%

0%

0%

0%

6

0%

4%

0%

0%

0%

0%

0%

0%

>0

43%

16%

14%

12%

14%

20%

14%

28%

0

57%

84%

86%

88%

86%

80%

86%

72%

1

36%

8%

14%

8%

0%

12%

0%

16%

2

0%

4%

0%

4%

7%

8%

7%

8%

3

7%

4%

0%

0%

7%

0%

7%

4%

>0

43%

24%

14%

8%

21%

8%

57%

20%

0

57%

76%

86%

92%

79%

92%

43%

80%

1

21.5%

8%

14%

4%

21%

8%

29%

20%

2

21.5%

4%

0%

4%

0%

0%

14%

0%

3

0%

4%

0%

0%

0%

0%

0%

0%

4

0%

4%

0%

0%

0%

0%

0%

0%

5

0%

0%

0%

0%

0%

0%

0%

0%

6

0%

4%

0%

0%

0%

0%

0%

0%
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Table 9
Hospital Contact Data for Full Sample
Percentage of Total Sample with Hospital Contact
12 Months Prior
to Index

3 Months
Prior to Index

3 Months
Post Index

6 Months
Post Index

Inpatient
Admission

31%

10%

13%

26%

ER visit

26%

13%

18%

23%

Category

As summarized in Table 10, the groups did not differ in a statistically significant
manner across time points or hospital variables of interest when analyzed using Fischer’s
exact tests. The Fischer’s exact test is the preferred choice for categorical data and
examining the contingency between two types of classifications as it provides an exact
calculation of deviation from the null hypothesis rather than an approximation. Since no
statistical difference was found between groups, treatment did not appear to have a
significant effect on outcome with regards to hospitalization data. Since a survivor
analysis would be most informative in the event of significant differences between
groups, it was omitted. However, examination of the groups across the 4 time points
does provide some additional context for understanding the null findings.
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Table 10
Results of Fischer’s Exact Tests Comparing Rate of Hospital Contact at Each Time Point
Hospital
Contact

–12 Months

–3 Months

3 Months

6 Months

Any

p = .11

p = 1.0

p = 1.0

p = .74

ER

p = .12

p = .33

p = .33

p = .12

Inpatient

p = .11

p = 1.0

p = 1.0

p = .12

As demonstrated in Figures 2-4, numerical differences were present between
groups across time points on each of the hospital criteria, albeit not statistically
significant differences. This analysis was completed by coding the data for each
participant in a binary yes or no fashion based on whether or not the participant had at
least one occurrence of the hospital criterion of interest from the given time period to the
index hospitalization. This allowed examination of any differences in hospitalization
data prior (which can be conceptualized as baseline pre-intervention data) that might be
relevant to the lack of differences in hospitalization data post-treatment. That is,
differences between groups can be examined as well as compared to the baseline data. In
order to consider that a treatment effect had occurred, a difference between groups would
have to be present post-intervention, but should also be significantly different than the
pre-intervention baseline data.
When examining any mental health related hospital visit across time, the ACT
group had a numerically higher percentage of individuals with hospital contact 12 months
prior to the index hospitalization (64% vs. 36%, p = .11) (see Figure 2). The ACT and
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TAU groups are nearly identical (21% vs. 20%, p = 1.0) in the 3-month prior and 3month post index data (29% vs. 28%, p = 1.0) with regard to any mental health related
hospital visit. They slightly diverge at the 6-month post time point, with 50% the ACT
group and 40% of the TAU group (p = .74) having a hospital contact. These data do not
suggest an effect of ACT or TAU in reducing mental health related hospital visits.

100%
90%
80%
70%
60%
50%

ACT

40%

TAU

30%
20%
10%
0%
- 12 mos

- 3 mos

+ 3 mos

+ 6 mos

Figure 2. Percent of each condition that had any mental health related hospital contact.

When comparing emergency room (ER) visits without inpatient admissions across
time, the ACT group had a numerically higher percentage of individuals with ER contact
12 months prior to the index hospitalization (43% vs. 16%, p = .12) (see Figure 3). These
differences were greatly narrowed in the 3-month prior to index hospitalization data with
14% of the ACT group having ER visits compared to 12% in TAU (p = 1.00). Post-index
data indicated that 14% of the ACT group had an ER visit at 3-months post-treatment
compared to 20% in the TAU group (p = 1.00), a reversal from baseline. At the 6-month
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data point, 14% of the ACT group had ER visits compared to 28% in the TAU condition
(p = .45).

50%
45%
40%
35%
30%
25%

ACT

20%

TAU

15%
10%
5%
0%
- 12 mos

- 3 mos

+ 3 mos

+ 6 mos

Figure 3. Emergency room visits without inpatient admission by condition.

Comparing inpatient admissions across time, the ACT group had 43% with
inpatient admissions in the 12 months prior to the index hospitalization compared to 24%
in TAU (p = .29) (see Figure 4). In the 3 months prior to the index hospitalization, 14%
of the ACT group had an inpatient stay compared to 8% in TAU (p = .61). Post-index
data indicated that 21% of the ACT group had an inpatient admission at 3-months followup compared to 8% of the TAU group (p = .33), a result that is fairly consistent with 3month prior baseline data. At the 6-month post time point, both groups appeared to move
toward a return to baseline pre-index hospitalization rates. In the ACT group 43% had an
inpatient hospitalization compared to 16% of TAU (p = .12). These data suggest that the
addition of ACT to TAU did not appear to have an effect in reducing the number of
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inpatient hospitalizations. The ACT group was admitted more frequently than the TAU
group; it appears that both groups are returning to pre-admission rates rather than ACT
having an iatrogenic effect.

100%
90%
80%
70%
60%
50%

ACT

40%

TAU

30%
20%
10%
0%
- 12 mos

- 3 mos

+ 3 mos

+ 6 mos

Figure 4. Inpatient admission by condition.

Given that both groups appeared to be demonstrating a return to baseline across
most measures of post-index hospital contact, it was important to attempt to determine if
the ACT group showed any significant changes on mechanisms of action as proposed by
the ACT theoretical conceptualization. In order to say that the ACT intervention was
delivered and received but was ineffective in influencing re-hospitalization rates,
significant differences should be evident on the measures of proposed mechanisms of
action between groups. If no significant differences occurred between groups from preto post-treatment on these measures when the variable of time was accounted for, then it
is difficult to determine if the treatment was ineffective or if the treatment was not
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delivered or received. As shown in Table 11, both groups demonstrated statistically
significant improvement across measures of depression and mechanism of action during
the course of the index hospitalization. The improvement on measures of depressive
symptomology was an expected finding considering the nature of inpatient
hospitalization and the criteria used for release. However, it is worth noting that both
groups demonstrated significant improvements on the measures of ACT mechanisms of
action as well.
No statistically significant differences were demonstrated between groups on any
of the measures intended to examine the mechanisms of action between treatment groups.
That is, ACT did not significantly move the proposed mechanisms of action in
comparison to TAU when analyzed at the group level. Additionally, there were no
significant trends consistently found across the measures, with half of the measures
moving in the direction of change for TAU and the other half moving in the direction of
change for ACT. These results suggest random variations in the measures and thus the
ACT intervention did not appear to move any of the process variables (i.e., ATQ-B,
AAQ) above and beyond the general improvement seen across both groups from pre to
post.

Table 11
Between-Groups Differences From Pre- to Post-Treatment
ACT

TAU

Effect

Measure

Pre

Post

Pre

Post

Time Effect

Time × Treatment

MADRS

43.86 (9.30)

22.43 (11.79)

42.68 (9.25)

21.25 (11.75)

F=91.31; p=.00

F=.00; p=.98

BDI-II

36.15 (10.57)

25.54 (13.00)

37.17 (13.57)

22.00 (15.69)

F=25.76; p=.00

F=.80; p=.38

AAQ-II

33.21 (9.16)

27.21 (10.44)

33.42 (12.27)

26.33 (11.43)

F=12.63; p=.00

F=.087; p=.77

ATQ-B

103.14 (28.18)

80.21 (33.87)

98.58 (33.32)

82.88 (36.86)

F=9.64; p=.00

F=.34; p=.57

ATQ-F

106.00 (28.40)

88.21 (33.71)

109.83 (34.74)

83.50 (38.00)

F=14.41; p=.00

F=.54; p=.47

EROS

17.83 (6.26)

24.36 (5.54)

19.88 (6.63)

24.29 (6.29)

F=27.68; p=.00

F=1.63; p=.21
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Since no differences in process variables were found between groups during the
course of the index hospitalization, the next step was to consider treatment differences on
these measures at 3- and 6-month follow-up. Unfortunately, there were not enough data
to analyze due to poor return of the mailed follow-up measures. Phone data were
collected for the MADRS and thus had the most complete follow-up data (25/39
collected at follow-up). The MADRS data (see Table 12) did not demonstrate any
significant differences between the ACT or TAU groups (F = .37, p = .69). The
collection of the BDI-II, AAQ-II, ATQ, and EROS did not yield a sufficient return (5/39
completed both 3- and 6-month follow-up) to allow for analysis.

Table 12
Between-Groups Differences Pre, Post, and 3-Month Follow-up
ACT
(n=14)

MADRS

TAU
(n=11)

Pre

Post

Follow

Pre

Post

Follow

Time Effect

Time ×
Treatment

42.72

20.18

15.28

42.78

25.5

18.21

F=39.63; p=.00

F=.37; p=.69

Changes occurring during the inpatient treatment interval were also examined by
determining whether participants experienced clinically significant changes in depressive
symptoms and reliable change on process measures. These data allow for examination of
between-group differences but also for examination of change indices linked to
theoretically proposed processes of change. For instance, distinguishing those who were
in the ACT condition and demonstrated movement on at least one ACT consistent
process variable and demonstrated a clinically significant movement on depressive
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symptomology from those in the ACT group that did not appear to move on a proposed
process variable or achieve a clinically significant change in depression. On the
MADRS, a criterion score of greater than or equal to 18 was used. This criterion is based
on data from a depressed outpatient sample suggested by Williams and Kobak (2008)
wherein this cut-off criterion achieved 87% sensitivity and 61% specificity in
discriminating depressed from non-depressed individuals. Next, a Reliable Change Index
(RCI; Jacobsen, Follette, & Revenstorf, 1984) score, a level of change that is beyond
what is likely due to measurement variability alone, was calculated using the

from two previous studies (Kobak et al., 2010; Williams & Kobak, 2008) and the
MADRS standard deviation (9.16) from the current study. The square root of the initial
standard deviation is multiplied by the square root of the reliability coefficient, which
allows for the calculation of the RCI. The RCI is calculated such that 95% of the time, a
value equal or greater than this would be due to change unrelated to the unreliability of
the measurement. The RCI for the MADRS was calculated to be 8.03. Therefore, a score
that demonstrated a reduction on the MADRS that was equal to or below 18 at post and
achieved a drop from pre- to post-treatment of greater than 8 points would be said to have
met criteria for a clinically significant change.
Clinically significant change was also calculated for the BDI-II. To do this, a
criterion score of less than 11 was determined from the literature for the BDI-II, which is
a standard cut off score use to determine depressed from non-depressed samples. A
standard deviation of 12.46 from the current sample was used with  from a
depressed geriatric inpatient sample (Steer, Rissmiller, & Beck, 2000). This resulted in a
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RCI score of 10.92; thus, anyone who demonstrated a reduction of 11 or more from pre to
post-treatment on the BDI resulting in a score of 10 or lower would be considered to have
demonstrated a clinically significant response.
For the process measures, no criterion cut-off scores are available as these
measures are not intended to be used for diagnostic purposes. Therefore, only the RCI
was calculated for these measures. For the ATQ-B, the standard deviation from the
current sample (31.21) was used with  from a depressed outpatient sample
depressed from the literature (Zettle et al., 2011). This resulted in an RCI of 19.34. Any
change of 20 or greater on the ATQ-B from pre to post was said to be a treatment
responder. For the ATQ-F, the standard deviation from the current sample (32.20) was
used with  from a depressed outpatient sample from the literature (Harrell &
Ryon, 1983). This resulted in an RCI of 21.86. Any change of 22 or greater on the
ATQ-F from pre to post was said to be a treatment responder
For the AAQ-II, the standard deviation from the current sample (11.09) was used
with  from a substance abusing inpatient sample from the literature (Bond et al.,
2011). This resulted in an RCI of 12.30. Any change of 13 or greater on the AAQ-II
from pre to post was said to be a treatment responder.
For the EROS, the standard deviation from the current sample (6.50) was used
with  from a normal college student population from the literature (Armento &
Hopko, 2007). This resulted in an RCI of 6.74. Any change of 7 or greater on the EROS
from pre to post was said to be a treatment responder. See Table 13.
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Table 13
Reliable Change and Cut Score Calculation Data

Measure

Co-efficient
Alpha

Standard
Deviation

Reliable Change
Index Score

Cut Score
Criterion

MADRS

.90

9.16

8.03

≥ 18

BDI-II

 .90

12.46

10.92

> 10

ATQ-B

.95

31.21

19.34

N/A

ATQ-F

.94

32.20

21.86

N/A

AAQ-II

.84

11.09

12.30

N/A

EROS

.86

6.50

6.74

N/A

The percent of each group that met the RCI was examined for each of the
depression and process measures. Significant differences were found on the ATQ-B (p =
.037) in favor of the ACT group (see Table 14). No other significant differences were
found between the groups on measure of process or depressive symptomology.

Table 14
Percentage of People in Each Group That Met the Reliable Change Index by Measure
Measure

ACT

TAU

p-value

MADRS

86% (n=14)

67% (n=24)

.268

BDI-II

39% (n=13)

50% (n=24)

.731

ATQ-B

64% (n=14)

25% (n=24)

.037*

ATQ-F

57% (n=14)

33% (n=24)

.187

AAQ-II

21% (n=14)

21% (n=24)

.635

EROS

42% (n=14)

33% (n=24)

.447
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Next, between-groups differences in clinically significant change were examined.
No statistical differences were found between the ACT and TAU groups when MADRS
(p = .396), BDI-II (p = .136), either measure (p = .219) or both measures (p = .328) were
compared (see Table 15). This suggests that the ACT intervention did not produce a
greater response to depressive type symptoms than TAU.

Table 15
Percentage of Treatment Responders by Group and Measure
Measure

ACT

TAU

p-value

MADRS

36%

46%

.396

7%

29%

.136

Both

15%

33%

.219

Either

36%

54%

.328

BDI-II

Given that there was a significant difference in the percentage of participants
demonstrating an RCI on the ATQ-B in ACT compared to TAU, the impact on 6-month
inpatient hospitalization rates of having received ACT and having reached criterion for an
RCI on the ATQ-B was examined. Of the 14 ACT participants, 4/6 (67%) who were
rehospitalized in the 6 months following the index admission met the criterion for an RCI
on the ATQ-B, which was similar to the percentage of participants in the subgroup that
was not rehospitalized that had an RCI on the ATQ-B, 5/8 (63%, p = 1.0). Thus, while
ACT appeared to produce differential rates of meeting the RCI on the ATQ-B, the
ATQ-B change was not predictive of later hospitalization.
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Given the absence of group differences in inpatient admissions between the
treatment conditions, we examined whether pretreatment variables were predictive of
having an inpatient admission in the 6 months following the index hospitalization. Ten
out of 39 patients (26%) were readmitted within 6 months. Patients were grouped by
whether they had an inpatient hospitalization or not in the 6 months following the index
hospital visit and compared on pretreatment variables of age, total number of
hospitalizations in the prior 12 months, IIP, MADRS, BDI-II, AAQ, ATQ-F, ATQ-B,
and EROS (see Appendix I). Two statistically significant differences were found. Those
who were re-hospitalized within 6 months had significantly lower mean scores on the
ATQ-F (x = 117.79(28.12) vs. x = 82.20(29.21); p = .002) and ATQ-B (x = 106.32(29.57)
vs. x = 83.30(30.77); p = 044). These results are counterintuitive as one might expect
those with lower frequency and believability of negative thoughts to be less, not more,
likely to be re-admitted. Multiple diagnoses on Axis I, co-morbid Axis I and Axis II, and
participants that exceeded a cut score of 1.1 on the IIP (the cut score that indicates a
probable personality disorder) were also examined. None of these pre-treatment
variables had a significant effect on 6-month inpatient admission (see Appendix H).
Also examined was whether any variables associated with improvement in
symptoms during the index hospitalization predicted readmission in the subsequent 6
months. Patients were grouped by whether they had an inpatient hospitalization or not in
the 6 months following the index hospital visit and compared on variables of length of
index hospitalization, discharge scores in the IIP, MADRS, BDI-II, AAQ, ATQ-F,
ATQ-B, and EROS, and change scores on the MADRS, BDI-II, AAQ, ATQ-F, ATQ-B,
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and EROS. No statistically significant differences were found (see Appendix J). Fisher’s
Exact Test examined the relationship between 6-month readmission status and clinically
significant change (on the MADRS and BDI) or reliable change (on the AAQ, ATQ, and
EROS) during the index hospitalization. No statistically significant differences were
observed.
Finally, given the individual differences in the ACT group (i.e., 6/14 = 43%
readmitted within 6 months), ACT related treatment variables were examined in attempt
to better characterize response (or lack thereof) within this group. Patients were grouped
by whether they had an inpatient hospitalization or not in the 6 months following the
index hospital visit and compared on hospitalizations in the prior 12 months, length of
index hospitalization, the amount of time spent with ACT therapist, the number of ACT
sessions, the quality of the ACT sessions, and change scores on the MADRS, BDI-II,
AAQ, ATQ-F, ATQ-B, and EROS. One statistically significant difference was found
(see Appendix H). The therapist rated quality of the ACT sessions in terms of
engagement was significantly higher among the 8 patients who were not rehospitalized in
the subsequent 6 months (M = 4.78, SD = .96) compared to the 6 who were (M = 3.58,
SD = 1.14), t(12) = 2.24, p = .05.
As presented previously, Fisher’s Exact Test examining the relationship between
6-month readmission status and reliable change on the AAQ and ATQ-B during the index
hospitalization revealed no statistically significant differences. Among the 8 ACT
recipients who were not rehospitalized, 5/8 (63%) showed a reliable change on the

59
ATQ-B, while among the 6 ACT recipients who were rehospitalized, 4/6 (67%) showed a
reliable change on the ATQ-B (p = 1.0).
The two preceding findings are interesting: therapist ACT session evaluations
predicted 6-month readmission rates, but reliable changes on the ATQ-B (an ACT
process measure in which ACT outperformed TAU) did not. Post hoc analyses further
examined the relationships between ACT session evaluations, reliable change on the
ATQ-B, and 6-month readmission likelihood. Nine participants had a RCI on the ATQ-B,
5 were not rehospitalized, 4 were. The mean (SD and range) ACT session evaluation was
5.25 (0.83, 4.0–6.0) for those who were not rehospitalized compared to 3.21 (1.23, 2.33–
4.5) for those who were, t = 2.99, p = .04. This is a small sample and post hoc analysis,
but the consistency is interesting as there was little overlap in the individual ACT session
evaluation scores between the two groups. Thus, there appears to be a subgroup that had
high therapist rated ACT session evaluations and evinced a reliable change on the
ATQ-B and it was this subgroup that went on to remain free of subsequent
hospitalizations in the next 6 months. Those who were readmitted had reliable change on
the ATQ-B, but lower ACT session evaluations (see Figure 5).
Among those who did not have an RCI on the ATQ-B, ACT session evaluations
had a mean of 4.0 (.60, 3.50–4.67) for the 3 who were not hospitalized and 4.33 (4.00 and
4.67) for the 2 who were hospitalized. Thus, to the extent that there was an ACT specific
effect for a subgroup who received ACT, it was associated with the combination of high
ACT session evaluations and a change on the ATQ-B.
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Figure 5. Individual ACT session evaluations and 6-month re-admission rates among the
9 participants showing a reliable change on the ATQ-B.

CHAPTER V
DISCUSSION
The present study found that brief individual Acceptance and Commitment
therapy did not significantly reduce the rate of subsequent hospital inpatient admission or
mental health related ER visits compared to treatment as usual. This was found to be the
case for not only for days from index hospitalization to the next mental health related
visit, but also when total numbers of post-index hospital visits were examined at 3- and 6month follow-up. Additionally, ACT did not appear to move the proposed mechanisms
of action above and beyond the general improvement seen across the sample during the
index hospitalization when compared at the group level. This is contrary to findings in
previous ACT studies that have shown that ACT intervention typically moves different
and theoretically consistent mechanisms of action when compared to other treatments
(Bach & Hayes 2002; Bach et al., 2012; Gaudinano & Herbert, 2006). Differences,
however, were found in favor of ACT on one measure of mechanism of action proposed
to be involved with ACT interventions, the ATQ-B, when the percent of participants that
had an RCI were examined by group. This could indicate that ACT, when received, was
better decreasing the believability of thoughts. This finding is consistent with previous
research (Bach & Hayes 2002; Bach et al., 2012; Gaudinano & Herbert, 2006; Zettle,
2005). However, these differences were not related to less frequent mental health related
hospital visits.
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Additionally, there were no statistically significant improvements on measures of
depression between groups at any time point. This is in contrast to findings that have
found ACT to differentially demonstrate improvement for depressed adolescents (Broten
& Gaynor, in preparation), adults (Zettle et al., 2011), and adult inpatients with comorbid substance abuse (Bond et al., 2011).
The lack of differential treatment effect on measures of depression and rehospitalization in the current study are in contrast to previous findings that have found
brief ACT interventions not only to have reduced re-hospitalization rates for patients with
severe and persistent mental illness (Bach & Hayes 2002; Bach et al., 2012; Gaudinano &
Herbert, 2006) but also to have done so according to proposed mechanisms of action.
One possible explanation for these findings is that the dosage or quality of ACT
sessions was not sufficient to move the mechanisms of action consistently and produce
meaningful change in a between-groups comparison. Some evidence to support this
hypothesis was found when the ACT group was analyzed by ATQ-B RCI and therapist
quality ratings, and examined by 6-month inpatient hospitalization rates. This analysis
indicated that ACT participants that had both an RCI on the ATQ-B and were rated
highly on the therapist rating of quality appeared to have reduced remittance to the
hospital. However, these groups are too small to make any statements with certainty.
Additionally, no measure of overall engagement in the treatment while on the inpatient
unit in the hospital was available; therefore, these participants may have been more
engaged in all modalities of treatment rather than just ACT. This makes it impossible to
determine if ACT engagement or overall engagement was the necessary component in
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reducing hospital recidivism. Additionally, the average amount of ACT delivered was
168 (80.25) minutes. In previous studies, the number of minutes was 180 minutes and
was standardized across participants. The variability and brief nature of the treatment
length raise questions about the quantity of ACT necessary to elicit change in such a
severe population.
Another reason the ACT treatment may have struggled to outperform TAU was
the robust nature of the TAU used in the study. The Borgess inpatient hospitalization
program for mood disorders involves several components included in the best practices
for inpatient hospitalization programs. Inpatient treatments vary greatly (Brabender,
1993), with medication management appearing to be the one “mainstay” across settings.
While no guidelines exist to detail the “gold standard” for inpatient care given the rather
limited outcome studies available, there is significant evidence suggesting that a
proactive community-based approach is indicative of improved outcomes for suicidal
patients (Jarrett, 1995). Additionally, programs that employ evidence-based treatments
for mood disorders would be likely to achieve more promising outcomes than programs
that employed eclectic or non-evidenced based interventions (Broten et al., 2011).
Borgess includes several of the suggested components including psychoeducation,
daily evidenced-based CBT based group therapy, medication management, as well as
community-based support and intervention (assistance in finding housing, connection to
outpatient therapeutic services, and social support, if deemed necessary). In spite of this
relatively intensive set of interventions, prospective rates of hospital recidivism for the
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program at Borgess Hospital appeared to be comparable to those collected from other
samples (Lin et al., 2009) who found a 57% rate at 1-year follow-up.
Finally, it is possible that the setting is not conducive to treatment outcome
research that is predicated on long-term improvement in symptomology. The nature of
inpatient hospitalization settings has shifted from a treatment orientation one of
stabilization. Increasing financial pressures have contributed to a decrease in the length
of hospitalization and frequently hospitals and patients are pressured to leave the
inpatient setting as soon as they no longer pose a risk to themselves or others. With this
shift in focus, inpatient units may not be a setting where long-term change in behavior or
decreased depressive symptomology should, or can, be expected. It may be more
beneficial to focus these interventions in outpatient or long-term inpatient care.
Limitations and Weaknesses
There are several limitations to the current study. The small sample size was a
significant limitation to the study. While the study did have enough subjects to detect
differences, these differences would have had to have been robust for statistical
significance. Depression is waxing and waning in nature and often achieves robust
placebo effects and a likely regression towards the mean. This is in contrast to other
conditions, such as psychosis, which have shown greater treatment response. The small
sample size may not have allowed for enough power to account for these effects.
However, given the small sample size, the direction of effects does not seem to suggest
that larger sample with similar results would have produced a statistically significant
difference in favor of ACT. The small sample size also limited the conclusions that can
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be drawn from post hoc analyses such as the investigation of ACT quality ratings,
ATQ-B RCI, and the relationship with 6-month rehospitalization.
Also, the lack of independently monitored treatment integrity does not allow us to
say with any certitude that the intervention delivered was ACT consistent or delivered
with sufficient competency. These concerns were addressed to a certain extent by
previous therapist training and experience administering an ACT based research protocol
as well as ratings of quality of the ACT sessions, but the nature of the hospital setting
would not allow for independent coding of videotaped sessions to ensure the adherence
and competency of the treatment. The variability in treatment length and treatment
quality also made accurate comparison between groups difficult. Determining how much
therapy and what level of quality to say a meaningful therapeutic interaction has occurred
has not been researched sufficiently.
There was also a significant difficulty in contacting research subjects to collect
follow-up data for self-report measures of depression and mechanisms of action. Given
the low SES and highly transient nature of the population, research subjects frequently
had moved residences, were living in shelters, or had their phone disconnected, making
collecting follow-up data difficult. This greatly impeded the ability to analyze the
follow-up data to determine if ACT had moved measures after the subjects had left the
hospital and had greater freedom to apply the intervention in practice. Given that
previous research has demonstrated that effects in ACT may become more robust over
time, these data would have been useful in determining if some participants also
continued to move on ACT process measures over time.
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Another possible limitation is that the nature of the inpatient program limited the
values-based activities that were available to the subjects. Since the values-based activity
portion of ACT most closely resembles another empirically supported intervention for
depression, Behavioral Activation, it can be hypothesized that this may one of the most
important components of ACT for the treatment of depression. It is possible that subjects
did not have an opportunity to try meaningful or “real world” activities, which may have
helped treatment generalization outside of the inpatient unit.
Additionally, given the general CBT orientation of the inpatient program at
Borgess, it is likely that subjects in the ACT condition may have heard different
approaches to dealing with thoughts and feelings. This may have impeded in the
understanding and retention of the newer and often counter intuitive ACT intervention.
The ACT intervention also took place at the end of the day, when patients may have been
less receptive to new material as they had received 4 hours of therapy previously in the
day.
As previously described, the inpatient program at Borgess is fairly robust and
intensive, and the population is typically a chronically depressed population. It is
possible that the gains made by the program are approaching the upper limit of recovery
for the limited treatment time and the level of severity at admission. Interventions to
decrease hospital recidivism may have to focus on changing contextual components of
the environment (finding work, marital therapy) or be supplemented outside of the brief
inpatient stay such as transitioning to a day treatment or intensive outpatient treatment
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program to help facilitate generalization. These are empirical questions that merit further
exploration.
Future research to determine the dosage of ACT required to achieve a meaningful
and clinically significant change is necessary. ACT has been demonstrated to be a brief
and powerful intervention for psychosis (Bach & Hayes, 2002; Bach et al., 2012;
Gaudinano & Herbert, 2006) and potentially adolescent depression (Broten & Gaynor, in
preparation); however, more research regarding the minimum amount of treatment
necessary to achieve these outcomes is needed. Additionally, exploration specific
mechanisms of action and their effect on treatment outcome may help improve the
effectiveness of brief ACT interventions. While ACT has more research demonstrating
change that is mediated by its theoretically proposed mechanisms of action then many
treatments, further exploration of techniques aimed at moving these proposed
mechanisms may help improve the potency of brief ACT interventions.
ACT may prove to be more useful as a post-hospitalization or continuation of care
intervention as opposed to an intervention for an acute, stabilization focused program for
depression. Future research should examine the utility of ACT for the prevention of
rehospitalization after stabilization has occurred, as this may be a more beneficial
utilization of resources.

REFERENCES
Addis, M. E., Truax, P., & Jacobsen, N. S. (1996). Why do people think that they are
depressed: The reasons for depression questionnaire. Psychotherapy, 32, 476-483.
American Psychiatric Association (APA). (1994). Diagnostic and statistical manual of
mental disorders (4th ed.). Washington, DC: Author.
American Psychiatric Association (APA). (2000a). Diagnostic and statistical manual of
mental disorders (text revision). Washington, DC: Author.
American Psychiatric Association (APA). (2000b). Practice guideline for the treatment of
patients with major depressive disorder (revision). American Journal of Psychiatry,
157, 1-45.
Armento, M. E. A., & Hopko, D. R. (2007). The Environmental Reward Observation
Scale (EROS): Development, validity, and reliability. Behavior Therapy, 38, 107119.
Augustson, E. M., & Dougher, M. J. (1997). The transfer of avoidance evoking functions
through stimulus equivalence classes. Journal of Behavior Therapy and
Experimental Psychology, 28, 181-191.
Bach, P., & Hayes, S. C. (2002). The use of acceptance and commitment therapy to
prevent the rehospitalization of psychotic patients: A randomized controlled trial.
Journal of Consulting and Clinical Psychology, 70(5), 1129-1139.
Bach, P., Hayes, S. C, & Gallop, R. (2012). Long-term effects of brief acceptance and
commitment therapy for psychosis. Behavior Modification, 36(2), 165-181.
Beck, A. T. (1976). Cognitive therapy and the emotional disorders. New York:
International Universities Press.
Beck, A. T., Rush, A. J., Shaw, B. F., & Emery, G. (1979). Cognitive therapy of
depression. New York: Guilford Press.
Beck, A. T., Steer, R. A., & Brown, G. K. (1996). Manual for the BDI-II. San Antonio,
TX: Psychological Corporation.
Beutler, L. E., Castonguay, L. G., & Follette, W. C. (2006). Therapeutic factors in
dysphoric disorders. Journal of Clinical Psychology, 62(6), 639-647.
68

69
Biglan, A., Hops, H., Sherman, L., Friedman, L., Artur, J., & Osteen, V. (1985). Problem
solving interactions of depressed woman and their husbands. Behavior Therapy, 16,
431-451.
Billings, A. G., & Moos, R. H. (1984). Chronic and nonchronic unipolar depression: The
differential role of environmental stressors and resources. The Journal of Nervous
and Mental Disease, 172, 65-75.
Bond, F. W., Hayes, S. C., Baer, R. A., Carpenter, K. M., Guenole, N., Orcutt, H. K.,
Waltz, T., & Zettle, R. D. (2011). Preliminary psychometric properties of the
Acceptance and Action Questionnaire – II: A revised measure of psychological
flexibility and experiential avoidance. Behavior Therapy, 42(4), 676-688.
Brabender, V. (1993). Inpatient group psychotherapy. In H. I. Kaplan & B. J. Sadock
(Eds.), Comprehensive group psychotherapy (3rd ed., pp. 607-619). Baltimore,
MD: Williams & Wilkins.
Broten, L. A., Naugle, A. E., Kalata, A. H., & Gaynor, S. T. (2011). Depression and a
stepped care model. In W. T. O’Donohue, & C. Draper (Eds.), Stepped care and
e-health (pp. 17-43). NewYork, NY: US: Springer Science + Business Media.
Busch, A. M., Kanter, J. W, Landes, S. J., & Kohlenberg, R. J. (2006). Sudden gains and
outcome: A broader temporal analysis of cognitive therapy for depression. Behavior
Therapy, 37, 61-87.
Cotterill, P. G., & Thomas, F. G. (2004). Prospective payment for Medicare inpatient
psychiatric care: Assessing the alternatives. Health Care Financing Review, 26, 85101.
DeRubeis, R. J., Hollon, S. D., Amsterdam, J. D., et al. (2005). Cognitive therapy vs.
medications in the treatment of moderate to severe depression. Archives of General
Psychiatry, 62, 409-416.
Dimidjian, S., Hollon, S. D., Dobson, K. S., Schmaling, K. B., Kohlenberg, R. J., &
Addis, M. (2006). Randomized trial of behavioral activation, cognitive therapy, and
antidepressant medication in the acute treatment of adults with major depression.
Journal of Consulting and Clinical Psychology, 74, 658-670.
Dobson, K. S. (1989). A meta-analysis of the efficacy of cognitive therapy for
depression. Journal of Consulting and Clinical Psychology, 57(3), 414.
Dobson, K. S., Hollon, S. D., Dimidjian, S., et al. (2008). Randomized trial of behavioral
activation, cognitive therapy, and antidepressant medication in the prevention of
relapse and recurrence in major depression. Journal of Consulting and Clinical
Psychology, 76, 468-477.

70
Domino, M. E., Burns, B. J., Silva, S. G., et al. (2008). Cost-effectiveness of treatments
for adolescent depression: Results from TADS. American Journal of Psychiatry,
165, 588-596.
Dougher, M. J., & Hackbert, L. (2000). Establishing operations, cognition, and emotion.
Behavior Analyst, 23(1), 11-24.
Dozois, D. J. A. (2003). The psychometric characteristics of the Hamilton Depression
Inventory. Journal of Personality Assessment, 80(1), 31-40.
Elkin, I. (1994). The NIMH Treatment of Depression Collaborative Research Program:
Where we began and where we are. In A. E. Bergin & S. L. Garfield (Eds.),
Handbook of psychotherapy and behavior change (4th ed., pp. 114-139). Oxford,
England: John Wiley & Sons.
Elkin, I., Shea, M. T., Watkins, J. T., et al. (1989). National Institute of Mental Health
Treatment of Depression Collaborative Research Program: General effectiveness of
treatments. Archives of General Psychiatry, 46, 971-982.
Fawcett, J. (2008). Is the current state of the treatment of depression satisfactory?
Psychiatric Annals, 37, 172.
Ferster, C. B. (1973). A functional analysis of depression. American Psychologist, 28,
857-870
First, M. B., Spitzer, R. L., Gibbon, M., & Williams, J. B. W. (1995). The structured
clinical interview for DSM-III-R personality disorders (SCID-II): I. description.
Journal of Personality Disorders, 9, 83-91
Friedman, E. S., Thase, M. E., Wisniewski, S. R., Trivedi, M. H., Biggs, M. M., & Fava,
M. (2009). Cognitive therapy augmentation versus CT switch treatment: A
STAR*D report. International Journal of Cognitive Therapy, 2(1), 66-87.
Gaudinano, B. A., & Herbert, J. D. (2006). Believability of hallucinations as a potential
mediator of their frequency and associated distress in psychotic inpatients.
Behaviour Research & Therapy, 44(3), 415-437.
Gloaguen, V., Cottraux, J., Cucherat, M., & Blackburn, I. M. (1998). A meta analysis of
the effects of cognitive therapy in depressed patients. Journal of Affective
Disorders, 49, 59-72.
Harrell, T. H., & Ryon, N. B. (1983). Cognitive-behavioral assessment of depression:
Clinical validation of the Automatic Thoughts Questionnaire. Journal of Consulting
and Clinical Psychology, 51(5), 721-725.

71
Hayes, S. C., Barnes-Holmes, D., & Roche, B. (Eds.). (2001). Relational frame theory: A
post-Skinnerian account of human language and cognition. New York:
Kluwer/Plenum.
Hayes, S. C., Luoma, J. B., Bond, F. W., Masuda, A., & Lillis, J. (2006). Acceptance and
commitment therapy: Model, processes and outcomes. Behaviour Research and
Therapy, 44(1), 1-25.
Hayes, S. C., Strosahl, K. D., & Wilson, K. G. (1999). Acceptance and commitment
therapy: An experiential approach to behavior change. New York: Guilford.
Herrnstein, R. J. (1970). On the law of effect. Journal of Experimental Analysis of
Behavior, 13, 243-266.
Hollon, S. D., DeRubeis, R. J., Shelton, R. C., et al. (2005). Prevention of relapse
following cognitive therapy versus medications in moderate to severe depression.
Archives of General Psychiatry, 62, 417-423.
Hollon, S. D., & Kendall, P. C. (1980). Cognitive self statements in depression:
Development of an automatic thought questionnaire. Cognitive Research and
Therapy, 4, 383-395.
Hollon, S. D., Thase, M. E., & Markowitz, J. C. (2002). Treatment and prevention of
depression. Psychological Science in the Public Interest, 3, 39-77.
Hopko, D. R., Lejuez, C. W., LePage, J. P., Hopko, S. D., & McNeil, D. W. (2003). A
brief behavioral activation treatment for depression: A randomized pilot trial within
an inpatient psychiatric hospital. Behavior Modification, 27(4), 458-469.
Hopko, D. R., Lejuez, C. W., Ruggiero, K. J., & Eifert, G. H. (2003). Contemporary
behavioral activation treatments for depression: Procedures, principles and
progress. Clinical Psychology Review, 23(5), 699-717.
Ilardi, S. S., & Craighead, W. E. (1994). The role of nonspecific factors in cognitive
behavior therapy for depression. Clinical Psychology: Science and Practice, 1, 138156.
Jacobson, N. S., Dobson, K. S., Truax, P. A., et al. (1996). A component analysis of
cognitive-behavioral treatment for depression. Journal of Consulting and Clinical
Psychology, 64, 295-304.
Jacobson, N. S., Follette, W. C., & Revenstorf, D. (1984). Psychotherapy outcome
research: Methods for reporting variability and evaluating clinical significance.
Behavior Therapy, 15(4), 336-352.

72
Jacobson, N. S. & Margolin, G. (1979). Marital therapy: Strategies based on social
learning and behavior exchange principles. New York: Brunner/Mazel.
Jarrett, R. B. (1995). Comparing and combining short-term psychotherapy and
pharmacotherapy for depression. In E. E. Beckham & W. R. Leber (Eds.),
Handbook of depression (2nd ed., pp. 435-464). New York: Guilford.
Kanter, J. W., Baruch, D. E., & Gaynor, S. T. (2006). Acceptance and commitment
therapy and behavioral activation for the treatment of depression: Description and
comparison. Behavior Analyst, 29(2), 161-185.
Kanter, J. W., Busch, A. M., Weeks, C. E., & Landes, S. J. (2008). The nature of clinical
depression: Symptoms, syndromes, and behavior analysis. Behavior Analyst, 31(1).
Kanter, J. W., Cautilli, J. D., Busch, A. M. & Baruch, D. E. (2005). Toward a
comprehensive functional analysis of depressive behavior: Five environmental
factors and a possible sixth and seventh. The Behavior Analyst Today, 6, 65-81.
Kanter, J. W., Mulick, P. S., Busch, A. M., Berlin, K. S., & Martell, C. R. (2007). The
behavioral activation for depression scale (BADS): Psychometric properties and
factor structure. Journal of Psychopathology and Behavioral Assessment, 29, 191202.
Kessler, R. C., Chiu, W. T., Demler, O., & Walters, E. E. (2005). Prevalence, severity,
and comorbidity of 12-month DSM-IV disorders in the national comorbidity survey
replication. Archives of General Psychiatry, 62(6), 617-627.
Kim, Y., & Pilkonis, P. A. (1999). Selecting the most informative items in the IIP scales
for personality disorders: An application of item response theory. Journal of
Personality Disorders, 13, 157-174.
Kobak, K. A., Leuchter, A., DeBrota, D., Engelhardt, N., Williams, J. B., Cook, I. A.,
Leon, A. C., & Alpert, J. (2010). Site versus centralized raters in a clinical
depression trial: Impact on patient selection and placebo response. Journal of
Clinical Psychopharmacology, 30(2), 193-197.
Kobak, K. A., Williams, J. B. W., Jeglic, E., Salvucci, D., & Sharp, I. R. (2008). Face-toface versus remote administration of the Montgomery-Åsberg Depression Rating
Scale using videoconference and telephone. Depression and Anxiety, 25(11), 913919.
Lejuez, C. W., Hopko, D. R., & Hopko, S. D. (2001). A brief behavioral activation
treatment for depression: Treatment manual. Behavior Modification, 25(2), 255286.

73
Lejuez, C. W., Hopko, D. R., & Hopko, S. D. (2002). The brief behavioral activation
treatment for depression (BATD): A comprehensive patient guide. Boston, MA:
Pearson Custom.
Lejuez, C. W. ,Hopko, D. R., LePage, J. P., Hopko, S. D., & McNeil, D. W.(2001). A
brief behavioral activation treatment for depression. Cognitive and Behavioral
Practice, 8, 164-175.
Lewinsohn, P. M. (1974). A behavioral approach to the treatment of depression. In R. M.
Freidman & M. M. Katz (Eds.), The psychology of depression: Contemporary
theory and research (pp. 157-185). New York: Wiley.
Lewinsohn, P. M., Rohde, P., Seeley, J. R., Klein, D. N., & Gotlib, I. H. (2000). Natural
course of adolescent major depressive disorder in a community sample: Predictors
of recurrence in young adults. American Journal of Psychiatry, 157(10), 15841591.
Lieberman, P. B., Wiitala, S. A., Elliott, B., McCormick, S., & Goyette, S. B. (1998).
Decreasing length of stay: Are there effects on outcomes of psychiatric
hospitalization? American Journal of Psychiatry, 155, 905-909.
Lin, M., Moyle, W., Chang, H., Chou, M., & Hsu, M. (2009) Effect of an interactive
computerized psychoeducation system on patients suffering from depression.
Journal of Clinical Nursing, 17, 667-676.
Maier, W., & Philipp, M. (1985). Comparative analysis of observer depression scales.
Acta Psychiatrica Scandinavica, 72(3), 239-245.
Malott, R. W. (1981). Notes from a radical behaviorist. Kalamazoo, MI: Author.
Montgomery, S. A., & Åsberg, M. (1979). A new depression scale designed to be
sensitive to change. British Journal of Psychiatry, 134, 382-389.
Overmier, J. B., & Seligman, M. E. P. (1967). Effects of inescapable shock upon
subsequent escape and avoidance responding. Journal of Comparative and
Physiological Psychology, 63(1), 28-33.
Persons, J. B., Davidson, J., & Tompkins, M. A. (2001). Essential components of
cognitive behavior therapy for depression. Washington, DC American
Psychological Association.
Petersen, C. L., & Zettle, R. D. (2009). Treating inpatients with comorbid depression and
alcohol use disorders: A comparison of acceptance and commitment therapy versus
treatment as usual. The Psychological Record, 59, 521-536.

74
Renaud, J., Brent, D. A., Baugher, M., Birmaher, B., Kolko, D. J., & Bridge, J. (1998).
Rapid response to psychosocial treatment for adolescent depression: A two-year
follow-up. Journal of the American Academy of Child and Adolescent Psychiatry,
37, 1184-1190.
Rohde, P., Silva, S. G., Tonev, S. T., et al. (2008). Achievement and maintenance of
sustained response during TADS continuation and maintenance therapy. Archives of
General Psychiatry, 65, 447-455.
Rush, J. A., Kilner, J., Fava, M., et al. (2008). Clinically relevant findings from STAR*D.
Psychiatric Annals, 38, 188-193.
Scogin, F., Jamison, C., & Gochneaur, K. (1989). Comparative efficacy of cognitive and
behavioral bibliotherapy for mildly and moderately depressed older adults. Journal
of Consulting and Clinical Psychology, 57, 403-407.
Sheeber, L., & Sorensen, S. (1998). Family relationships of depressed adolescents: A
multimethod assessment. Journal of Clinical Child Psychology, 27, 268-277.
Skinner, B. F. (1953). Science and human behavior. New York: McMillan.
Steer, R. A., Brown, G. K., Beck, A. T., & Sanderson, W. C. (2001). Mean Beck
Depression Inventory–II scores by severity of major depressive disorder.
Psychological Reports, 88(3), 1075-1076.
Steer, R. A., Rissmiller, D. J., & Beck, A. T. (2000). Use of Beck Depression Inventory–
II with depressed geriatric inpatients. Behaviour Research and Therapy, 38(3), 311318.
Sullivan, A. M., Barren, C. T., Bezmen, J., Rivera, J., & Zapata-Vega, M. (2005). The
safe treatment of the suicidal patient in an adult inpatient setting: A proactive
preventive approach. Psychiatric Quarterly, 76, 67-83.
Takahashi, N., Tomita, K., Higuchi, T., & Inada, T. (2004). The inter-rater reliability of
the Japanese version of the Montgomery-Åsberg Depression Rating Scale
(MADRS) using a structured interview guide for MADRS (SIGMA). Human
Psychopharmacology: Clinical and Experimental, 19(3), 187-192.
Valenstein, M., Kim, H. M., Ganoczy, D., McCarthy, J. F., Zivin, K., Austin, K. L., et al.
(2009). Higher-risk periods for suicide among VA patients receiving depression
treatment: Prioritizing suicide prevention efforts. Journal of Affective Disorders,
112, 50-58.
Williams, J. B. W., & Kobak, K. A. (2008). Development and reliability of a structured
interview guide for the Montgomery-Åsberg Depression Rating Scale (sigma).
British Journal of Psychiatry, 192(1), 52-58.

75
Wilson, K. G., & Groom, J. (2002). The Valued Living Questionnaire. Unpublished
manuscript, University of Mississippi, Oxford.
World Health Organization. Depression. Retrieved December 27, 2010, from
http://www.who.int/mental_health/management/depression/deﬁnition/en/
Zettle, R. D. (2005). The evolution of a contextual approach to therapy: From
comprehensive distancing to ACT. International Journal of Behavioral
Consultation and Therapy, 1, 77-89.
Zettle, R. D., & Hayes, S. C. (1986). Group comprehensive distancing treatment manual.
Unpublished manuscript, Wichita State University, Kansas.
Zettle, R. D., & Rains, J. C. (1989). Group cognitive and contextual therapies in
treatment of depression. Journal of Clinical Psychology, 45(3), 436-445.
Zettle, R. D., Rains, J. C., & Hayes, S. C. (2011). Processes of change in acceptance and
commitment therapy and cognitive therapy for depression: A mediation reanalysis
of Zettle and Rains. Behavior Modification, 35(3), 265-283.

Appendix A
Acceptance and Commitment Therapy for the Treatment of Depression

76

77
Acceptance and Commitment Therapy for the Treatment of Depression

Sessions should follow the following format:
 Brief Update and Mood Check
 Bridge from Previous Session
 Set Agenda
 Review Homework
 Potential supporting exercises (see below)
 Final Summary
 Assign Homework
 Feedback
Session-by-Session Information: Objectives, Possible Strategies, and Suggested
Homework Assignments
Note: The therapist should attempt to move sequentially through the below list of
components while recognizing that to maximize the fit to the client’s issues, it may be
necessary to alter the exact sequence of components, as well as omit or revisit certain
components. It is to be expected that some of these components would be discussed over
multiple sessions.
Session 1
 Objectives:
o The objective of this session is to induce Creative Hopelessness by
soliciting goals and failed attempts to achieve those goals as a way of
examining the unsuccessful client’s use of control strategies to cope with
depression. The therapist should also begin to understand the depression
presentation from an ACT perspective (examples of fusion, emotional
control strategies, distance from values).
 Potential supporting exercises:
o Solicit basic goals from the client
o Solicit past attempt to accomplish those goals
o Finger trap exercise / Quicksand metaphor
o Discuss where energy has been spent – where it could be redirected
o Initial Lemon exercise (don’t think about a lemon)
o Values explanation
 Homework:
o Mini Values Bull’s eyes
Session 2
 Objectives:
o The objective of this session is to elaborate on the prior session’s
conclusion that the client’s depressive state shows limited responsiveness
to control strategies. Experiential exercises should be used to further test
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the efficacy of control strategies. Therapist should introduce the idea that
“control is the problem, not the solution.” The therapist should also teach
client about the relationship between depressed mood and behavior using
examples from the client’s own life, and aim to increase the client’s
engagement in activities to engender a sense of mastery or pleasure.
Potential supporting exercises:
o Mind is not your friend
o Flat tire metaphor
o Mind and body misinformation discussion
o Reason giving + Ice cream metaphor
o “but” & “and” exercise
o Initial behavioral goal setting
Homework:
o Performance of initial identified behavioral goal

Session 3
 Objectives:
o The objective of this session is to continue to draw on the client’s
experience to strengthen the recognition that “control is the problem,” and
to introduce more defusion strategies related to thoughts and feelings.
Therapist should also troubleshoot difficulties with behavioral activation,
so as to increase the likelihood of the client’s success.
 Potential supporting exercises:
o Apparent success of deliberate emotional control
o How can you live a valued life with pain/ how could you without it?
o Clean v Dirty pain
o Evaluation v fact (pick me up at the airport exercise)
o Lemon Exercise 2: (Milk Milk Milk defusion)
o Trash can exercise
o Identification of simple behavioral goal requiring the patient to act while
experiencing emotion
 Homework:
o Performance of identified behavioral goal with emotion
o Thoughts on cards
Session 4
 Objectives:
o The objective of this session is to assess the client’s ability to defuse from
depressive thoughts and feelings and to introduce additional practical
ways to foster defusion as well as to foster self as context and introduce
mindfulness.
 Potential supporting exercises
o Breathing regulation (mindful breathing)
o Practice sitting with pain/noticing thoughts associated with pain
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Sand in a jar exercise
“I’m having the thought that . . .”
Breath and labeling practice (I feel_____ and I am going to do _____)
Experiential practice with doing valued activity and negative thoughts
(adapted from taking your mind for a walk) write a note telling someone
how you feel while therapist criticizes.
Homework:
o Performance of identified behavioral goal
o Mindful breathing and sitting with feelings practice

Session 5
 Objectives:
o The objective to explore the relationship between goals and actions, and to
firmly root components of Willingness and Defusion in the service of
achieving behavioral goals and discuss how to deal with barriers. Teach
the client to be his or her own therapist. To maximize the likelihood that
the client will continue to apply skills learned in therapy after termination.
To address client’s concerns about termination, if applicable. To prepare
for post-termination setbacks.
 Potential supporting exercises
o If “hot” emotions come up – sitting with feelings
o Role of choice in committed actions (review choice vs.
judgments/decisions): Why to choose you direction – because everyone
else has their own interests in mind )
o Barriers to goals and willingness to accept them: Bubble in the Road
Metaphor
o Willingness is like jumping exercise
o Solve the solvable discussion
o ACT acronym (Accept, Choose, Take Action)
o Identify a valued action (behavioral goal) to perform this week
o Record goals for self (i.e., in 1 month, 6 months, 1 year)
 Homework:
o Performance of identified valued action
Weekly Booster Sessions (subsequent sessions without impending termination)
Objectives
 Objectives:
o Continue to emphasize the components most relevant to specific client
issues. Homework should continue to feature Behavioral Activation in the
form of making commitments to specific actions that are inspired by the
client’s larger goals and values.
 Possible Strategies:
o All consistent ACT metaphors and exercises as needed
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Homework:
Homework should continue to feature Behavioral Activation in the form of
making commitments to specific actions that are inspired by the client’s larger
goals and values.
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Borgess Medical Center
INFORMED CONSENT FOR RESEARCH STUDY
1. GENERAL INFORMATION ABOUT THIS STUDY AND THE RESEARCHERS
1.1 Study Title:
THE USE OF A BRIEF ACCEPTANCE AND COMMITMENT THERAPY
PROTOCOL TO PREVENT REHOSPITALIZATION OF DEPRESSED
PATIENTS: A RANDOMIZED CONTROLLED TRIAL
1.2 Company or agency sponsoring the study:
Western Michigan University, Department of Psychology
1.3 Names, degrees, and affiliations of the researchers conducting the study:
Scott Gaynor, Ph. D.; Professor, Western Michigan University
Lucas Broten, M.A.; Clinical Psych Graduate Student, Western Michigan University
BK. Ramesh, M.D.; Michigan State University, Kalamazoo Center for Medical Studies
Robert Flachier, Ph.D; Michigan State University, Kalamazoo Center for Medical Studies

INFORMATION ABOUT THIS FORM
You may be eligible to take part in a research study. This form gives you important
information about the study. It describes the purpose of the study and the risks and
possible benefits of participating in the study.
Please take time to review this information carefully. After you have finished, you
should talk to the researchers about the research study and ask them any questions
you have. You may also wish to talk to others (for example, your friends, family, or
other doctors) about your participation in this study. If you decide to take part in
the study, you will be asked to sign this form. Before you sign this form, be sure you
understand what the study is about, including the risks and possible benefits to you.

2. NATURE AND PURPOSE OF THIS RESEARCH STUDY
2.1 Study Purpose:
This research study is intended to compare a therapy for depression for inpatients plus
standard treatment to see if it is better at preventing future hospitalizations than the
current standard treatment of the inpatient unit. This study is Lucas Broten’s dissertation
project.
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3. RESEARCH STUDY PROCEDURES
3.1 What exactly will be happen to me in this study? What kinds of research procedures will I
receive if I agree to take part in this study?

The principal investigator of this research study is Scott Gaynor, Ph. D. of Western
Michigan University. If you agree to participate in this study, you will be assigned to one
of two treatment groups.


Group 1 is Treatment As Usual, which includes meetings with a psychiatrist, case
manager, group therapy and educational groups. This is the standard care that any
patient admitted to the inpatient unit would receive, except you will be asked to
participate in five assessment sessions with the researcher.



Group 2 receives therapy in addition to the normal standard of care provided by
Borgess Medical Center as described above, it will include individual discussions
with the research therapist Lucas Broten, using a treatment called Acceptance and
Commitment Therapy (ACT). ACT is a therapy that attempts to help people
become more aware of promote acceptance of thoughts and feelings while helping
people engage in more meaningful and rewarding activities.

All subjects will take part in an initial assessment session, which will consist of clinical
interviews and paper and pencil questionnaires and will take approximately 50 minutes to
complete. All subjects will also participate in an assessment session just before they are
discharged from the hospital and at three, six and 12 months after discharge. These
assessment sessions are about 50 minutes long. In addition to the assessments at three,
six and 12 months, the researchers will also look at your electronic medical record to see
if you have been rehospitalized during this period and to record any hospitalizations in
the year prior to when you were admitted to the hospital.
3.2 How much of my time will be needed to take part in this study? When will my participation
in the study be over?

In addition to the initial assessment, if you are assigned to participate in the therapy
group, the therapy will take place in 50-minute sessions over the length of your stay.
After completing five therapy sessions, a once per week booster session will take place
every week that you are still admitted to the inpatient unit. The total one-on-one therapy
time for this study is between 1 and 18 hours depending on the length of your stay and is
completed while you are admitted to the hospital. You will also be asked to participate in
four future assessment sessions.
In total, if you are assigned to the therapy group will be asked to participate in between
6.25 and 21.25 hours of assessment and therapy in addition to the standard care provided
in the inpatient unit. The average amount of time is expected to be about 11.5 hours, but
might differ depending on the length of your hospital stay.
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If you are assigned to the Treatment As Usual group, you will be asked to participate in 5
hours of assessment in addition to the standard care provided in the inpatient unit. In
addition to the initial assessment, which lasts 50 minutes, you will participate in another
assessment session that will take approximately 50 minutes prior to discharge. You will
also be asked to participate in an identical assessment at three, six, and 12 months after
your discharge. You may be able to complete these sessions over the phone if you are
not able to attend in person.
Participation in the research study will be over after you have been contacted and
completed your final assessment at 12 months post discharge or at any time if you decide
that you do not wish to continue with the study.

4. EXPLANATION OF PROCEDURE TO BE FOLLOWED
Procedure
Whether you get the research study therapy or the Treatment As Usual will be randomly
assigned using a weighted random assignment, meaning you have a 1 in 3 chance of
getting the therapy if you choose to participate. You will have a 33% chance of getting
the study therapy and a 66% chance of getting Treatment As Usual. That means for each
participant assigned to therapy, two will be assigned to Treatment As Usual.
If you are assigned to Treatment As Usual you will be assigned a study number and asked
to participate in an hour and fifteen minute long assessment session. The researcher will
look at your electronic medical record to gather study relevant information and determine
if you qualify for the study. You will then participate in the normal activities of the
inpatient unit with the exception that you will attend an additional assessment sessions
before you are discharged that will take approximately 50 minutes. You will also be
asked to participate in an assessment at three, six, and 12 months after your discharge and
your medical records will be examined at these times. You may be able to complete
these sessions over the phone if you are not able to attend in person.
If you are assigned to the therapy group, you will you will be assigned a study number
and asked to participate in an hour and fifteen minute long assessment session. The
researcher will look at your electronic medical record to gather study relevant
information and determine if you qualify for the study. You will then participate in the
normal activities of the inpatient unit with the exception that you will attend additional
individual therapy sessions with the researcher. These sessions will take place in the
evenings after the activities typically involved in the inpatient treatment. If you are still
admitted to the hospital after the initial five sessions, you will meet for one additional
session for every week you remain in the hospital.
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You will then participate in the normal activities of the inpatient unit with the exception
that you will attend an additional assessment sessions before you are discharged that will
take approximately 50 minutes. You will also be asked to participate in an assessment at
three, six, and 12 months after your discharge and your medical records will be examined
at these times. You may be able to complete these sessions over the phone if you are not
able to attend in person. These assessment session will either take place at Borgess
Medical Cneter or Western Michigan University based on your preference. You will be
responsible for travel to and from the assessment sessions after discharge if you choose to
attend in person. Results of assessments and important information regarding your
treatment disclosed during therapy sessions may be shared with the Borgess staff. At
your request, the researcher may share information regarding your treatment and
assessments with professionals such as your doctor, therapist, etc., to assist in your
treatment after discharge. No information will be shared with persons outside of Borgess
Medical Center without your consent.
During the follow-up assessment sessions, you will be asked about how you are
progressing with your depressed thoughts and feelings through a series of paper and
pencil measures and an interview by your therapist. If you are determined to be at risk
for suicide, homicide, or are suspected of neglect or abuse, the therapist will provide
crisis management, facilitate a referral to appropriate (crisis or non-crisis) service
providers, and/or provide open treatment to the participant at the WMU Psychology
Clinic (which is run by the Psychology Department and where the Principal Investigator
is one of the supervisors) or alert a current therapist if necessary. The research therapist is
a doctoral candidate who has had significant coursework related to psychopathology and
experience working as a therapist in an outpatient clinical setting. The research therapist
and will be supervised by the Principal Investigator. Anytime a participant is referred to
these outside services, an adverse event report will be completed by the research therapist
in consultation with the Principal Investigator, Dr. Gaynor and reported to the Borgess
Medical Center IRB as well as to the Western Michigan University Human Subjects
Review Board. The IRB is a committee that has reviewed this study to help ensure that
your rights and welfare as a research subject are protected and that the study is carried out
in an ethical manner.
Taking part in this research study is completely voluntary. You do not have to
participate if you do not want to. You may also leave the study at any time. Refusal to
participate in this study will in no way jeopardize your treatment at the hospital or any
relationship with Western Michigan University in the present or future. If you leave the
study before it is finished, there will be no penalty to you and you will not lose any
benefits to which you are otherwise entitled.
Your participation in this research study may also be stopped, without your consent, by
the principal or student investigator if, in their opinion, your safety or well being is in
question.
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4.2 Who can take part in this study?

Any patient admitted to the Borgess Inpatient Depression Unit over the age of 18 with the
following exclusions: primary diagnosis of a non-depressive disorder such as a formal
diagnosis:
 mental retardation
 autism
 severe obsessive-compulsive disorder
 panic disorder
 schizophrenia
 psychotic disorders.
Finally, those who are non-English speaking or whose primary residence is outside of the
area covered within the electronic medical record computer system database use by
Borgess would be excluded.
4.3 How many people (subjects) are expected to take part in this study?

Sixty participants are expected to complete the research study, with about twenty in the
therapy group and forty in the Treatment As Usual group.

5. POTENTIAL BENEFITS
5.1 How could I benefit if I take part in this study? How could others benefit?

You may not receive any personal benefits from being in this research study.
For those assigned to the Treatment as Usual group, you may not receive any benefit
from participating in this study other than helping add to the research base for this
treatment.
You may receive several one-on-one therapy sessions involving ACT, which you would
not have received in the standard treatment as usual, and may assist in preventing relapse
and future hospitalization at no cost. In addition, as improvement is expected to occur,
important carryover effects such as improved academic, social, and family functioning
might occur.
Not many studies have been conducted with inpatients and ACT, therefore, this research
study may add to the body of literature.
Participating in research may provide information that will benefit other patients
with depression in the future.
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6. POTENTIAL RISKS
6.1 What risks will I face by taking part in the study? What will the researchers do to protect
me against these risks?

Known risks to you will be minimal. There are no known physical or economic risks.
Like any treatment, it is possible you will not improve despite following the treatment
protocol, which could lead to some worsening of feelings. Because the intervention
involves frequent meetings with monitoring of symptoms at each meeting, any such
worsening of symptoms should be readily detected and the therapist investigator can
attempt to address them as part of your treatment. However, should you experience a
dramatic worsening of symptoms, the therapist investigator will alert the staff of Borgess
Medical Center to assist you. Due to the nature of the setting, trained staff and support are
readily available should you need additional support.
In all research, there is the risk of disclosure of personal information. Upon signing the
written consent document, all information regarding the participant will be placed into a
folder with a randomly assigned number on it. All data collected from you will be
referred to by this number. Your name and the number will be recorded on a master list
by the researcher and this will be stored in a locked cabinet on campus to protect client
privacy and personal information. During transportation of this data from Borgess to
Western Michigan University, your data will be stored in a locked briefcase.
6.2 What happens if I get hurt, become sick, or have other problems as a result of this research?

In the event that you may be upset by the content of the assessments or the therapy
protocol, you can request to discontinue the session at anytime or discontinue the study at
any time with no repercussions.
If an accidental injury occurs, appropriate emergency measures will be taken.
However, no compensation or treatment will be made available except as otherwise
specified in this consent form.
The researchers have taken steps to minimize the known or expected risks.
However, you may still experience problems related to discussing uncomfortable
topics, even when the researchers are careful to avoid them. If you believe that
you have been harmed, notify the researchers listed in Section 9 of this form. By
signing this form you do not give up any of your legal rights as a patient or
research subject.
Please note: It is important that you tell the researchers about any injuries or other
problems that you experience during this study.
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7. ALTERNATIVE TREATMENTS
7.1 If I decide not to take part in this study, what other options do I have?

Your alternative is to simply participate in the standard treatment provided by the
Borgess inpatient depression unit.

8. PARTICIPANT COMPENSATION
8.1 Will taking part in this study cost me anything? Will I be billed for any costs of the study?

All assessments, therapy sessions, and research study medications for this study are
provided to you without charge.
8.2 Will I be paid or given anything for taking part in this study?

You are not paid for participating in the research study, but you will receive assessment
and potentially several individual therapy sessions at no cost to you.

9. PHYSICIAN COMPENSATION
9.1 Who could profit or financially benefit from the study results?

There is no financial benefit for the researcher or anyone affiliated with the project; the
research study is a thesis project. Dr. Ramesh, a physician at MSU/KCMS, and Dr.
Flachier, a psychologist are participating on a voluntary basis.

10. VOLUNTARY PARTICIPATION/RIGHT TO WITHDRAW FROM THIS
RESEARCH STUDY
10.1 If I want to stop participating in the study, what should I do?

This research study is for Lucas Broten’s dissertation. You are free to leave the
research study at any time. If you leave the study before it is finished there will be
no penalty to you and you will not lose any benefits to which you may otherwise be
entitled. If you choose to tell the researchers why you are leaving the study, your
reasons for leaving may be kept as part of the study record. If you decide to leave
the study before it is finished, please notify one of the persons listed in Section 11
“Contact Information” (below).
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10.2 Could there be any harm to me if I decide to leave the study before it is finished?

There is no harm to leaving the research study at any time, although be aware that
without going through the entire therapy treatment, benefits associated with the treatment
may not occur.
10.3 Could the researchers take me out of the study even if I want to continue to participate?

Yes. There are many reasons why the researchers may need to end your participation in
the research study. Some examples are:





The researcher believes that it is not in your best interest to stay in the study.
You become ineligible to participate.
You do not follow instructions from the researchers.
The study is suspended or canceled.

11. CONTACT INFORMATION
11.1 Who can I contact about this study?

Please contact the researchers listed below to:





Obtain more information about the research study
Ask a question about the study procedures
Leave the study before it is finished
Express a concern about the study
Principal Investigator: Scott Gaynor, Ph. D.
Mailing Address: Department of Psychology, Room 3700 Wood Hall; Western
Michigan University; Kalamazoo, MI 49008-5439
Telephone: (269)-387-4482
Student Investigator: Lucas Broten, M.A.
Mailing Address: Clinical Psychology, Room 3500 Wood Hall; Western
Michigan University; Kalamazoo MI 49008-5439
Telephone: (269) 387-4482

Collaborating Investigator: B.K. Ramesh, M.D.
Michigan State University, Kalamazoo Center for Medical Studies
Telephone: (269) 532-3650
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Collaborating Investigator: Roberto Flachier, Ph.D.
Michigan State University, Kalamazoo Center for Medical Studies
Telephone: (269) 532-3650
You may also express a concern about a research study by contacting the Institutional
Review Board (IRB) and/or Human Subjects Institutional Review Board (HSIRB) listed
below.
Borgess Medical Center Institutional Review Board
1521 Gull Road
Kalamazoo MI 49048
IRB chairperson: Richard Lammers, MD
Telephone: 269-226-7341
Fax: 269-226-6696
e-mail: research@borgess.com
Western Michigan University Human Subjects Review Board
HSIRB chairperson: Amy Naugle, Ph.D.
Telephone: 269-387-8293
If you are concerned about a possible violation of your privacy, contact the Borgess
Health Privacy Officer at 269-226-8409.
When you call or write about a concern, please provide as much information as possible,
including the name of the researcher, the study title (page 1 of this form), and details
about the problem. This will help Borgess officials to look into your concern. When
reporting a concern, you do not have to give your name unless you want to.

12. PROTECTED HEALTH INFORMATION (HIPAA)
Borgess Medical Center policies require that private information about you be protected.
This is especially true for your personal health information.
On the other hand, sometimes the law allows or requires others to see your information.
The information given below describes how your privacy and the confidentiality of your
research records will be protected in this study.
12.1 How will the researchers protect my privacy?

This authorization is voluntary and any healthcare treatment you may seek will not be
conditioned upon your signing this authorization. Signing this form gives the
researchers, identified in Section 1.3, your permission to obtain, use, and share
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information about you for this study, and is required in order for you to take part in the
study. Information about you may be obtained from any hospital, doctor, and other
health care provider involved in your care, as identified in section 6.
Information about you will include information about your health and your medical care
before, during, and after the study. For example:
 Hospital/doctor's office records for one year prior to and one after your
hospitalization
 General demographic information including age, sex, income, and employment
status.
 All records relating to your condition, the treatment you have received, and your
response to the treatment

There are many reasons why information about you may be used or seen by the
researchers or others during this study. Examples include:
 The researchers may need the information to make sure you can take part in the
study.
 The researchers may need the information to check your test results and
hospitalization history and re-admittance.
 Borgess and government officials may need the information to make sure that the
study is done properly.
 Safety monitors or committees may need the information to make sure that the
study is safe.
 Insurance companies or other organizations may need the information in order to
pay your medical bills or other costs of your participation in the study.
 The researchers may need to use the information to create a databank of
information about your condition or its treatment.
The results of this study could be published in an article, but would not include any
information that would let others know who you are.
Applicable federal and state laws protect information used or disclosed pursuant to this
consent. However, information that is released may be subject to redisclosure by the
recipient and will no longer be protected by these laws.
12.2 What happens to information about me after the study is over or if I cancel my
permission?

As a rule, the researchers will not continue to use or disclose information about
you, but will keep it secure until it is destroyed after a period of five years.
Sometimes, it may be necessary for information about you to continue to be used
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or disclosed, even after you have canceled your permission or the study is over.
Examples of reasons for this include:




To avoid losing study results that have already included your information
To provide limited information for research, education, or other activities (This
information would not include your name, social security number, or anything
else that could let others know who you are.)
To help Borgess, Western Michigan University and government officials make
sure that the study was conducted properly
If you decide not to give permission to release your personal health information
during this informed consent process or before you are enrolled into the research
study, you may not be able to participle in the study. This is because the study
researcher and/or his/her/staff would not be able to collect the information needed
to fully evaluate the study. If you do not authorize the use and disclosure of your
protected health information or cancel it in the future, your current or future
medical care will not be affected.

12.3

When does my permission expire?

Your permission expires at the end of the study, unless you revoke it sooner. You may
revoke your permission at any time by writing to the researchers listed in Section 12
"Contact Information," but this will not affect disclosures made prior to receipt of the
revocation.
13. SIGNATURES (CONSENT)
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Research Subject:
I have read this form, discussing the information of the research study investigating the
use of Acceptance and Commitment Therapy for Depression. I have read this informed
consent document. I have discussed this study, its risks and potential benefits, and my
other choices with researcher Lucas Broten. My questions so far have been answered. I
understand that if I have more questions or concerns about the study or my participation
as a research subject, I may contact one of the people listed in Section 11 (above). I
understand that I will receive a copy of this form at the time I sign it and later upon
request. I understand that if my ability to consent for myself changes, I may be asked to
re-consent prior to my continued participation in this study. This consent document has
been approved for use for one year by the Human Subjects Institutional Review Board
(HSIRB) as indicated by the stamped date and signature of the board chair in the upper
right hand corner. Do not participate in this study if the stamped date is older than one
year.
Signature of Subject: __________________________
Name (Print legal name):

Date: ________

__________

Signature of Person Explaining Consent_______________________ Date: _________
Name of Person Explaining Consent (Printed)___________________________________

Appendix C
Demographic Information Sheet
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Demographic Information Sheet
Study Name: ___________________________________________________
Pt. Study ID #: ____________________
Pt. DOB: ___________________

(DD-MMM-YYYY)

Current Primary Diagnosis:
________________________________________________________
Secondary Diagnoses:
_____________________________________________________________
Race/Ethnicity (circle the most appropriate):
Euro-American/White

African-American/Black Hispanic-American/Latino(a)

Asian-American

American Indian

Arab-American

Alaskan American

Multiracial

International/Non-US resident

Other _________________
________________________________________________________________________
Household Information
What is the combined income of all the adults living in the household where the
participant spends most nights each week?
Less than $5,000
$20,000-24,999
$75,000-99,999

$5,000-10,000
$10,000-14,999
$25,000-34,999
$35,000-49,999
More than $100,000

$15,000-19,999
$50,000-74,999

Number of children that the participant cares for:
0

1

2

3

4

5

6

7

8

9

10+

Marital Status (circle the most appropriate):
Single

Married

Domestic partnership

Engaged

Separated

Widowed

Divorced/annulled

Other:____________
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Education Level (circle the most appropriate):
Did not graduate high school General Educational Development (GED) Test
Graduated high school

Completed some college

Graduated 2-year college or technical school degree
Graduate 4-year college

Some graduate school

Graduate degree (Ph.D., MA, MS, MD)
Occupational Status (circle the most appropriate):
Employed

Unemployed

On disability

Retired

Other: __________________

Stay at home parent

Appendix D
Human Subjects Institutional Review Board
Letter of Approval
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Recruitment Script for Borgess Staff
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Recruitment Script for Borgess Staff
“Western Michigan University and Borgess Medical Center are currently working
together on a research study. This study is for patients, like yourself, who have been
admitted to the inpatient depression unit here at Borgess. The study is offering the
possibility of additional assessment and individual treatment free of charge that is geared
specifically towards depression and the prevention of future hospitalizations.
Participation includes 5.25 hours of assessment, and the possibility of up to 8 hours of
individual therapy in addition to the typical services in the Borgess inpatient unit. If you
would like to learn more and find out if you qualify for this study, please tell the Borgess
staff and they will schedule a meeting with a researcher where you can hear more about
the study.”

Appendix F
Follow-up Data Collection Sheet
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Follow-up Data Collection Sheet

Participant ID # ______________________________
Readmitted

YES / NO

Mental Health Related

YES / NO

Date of readmission __________________________________
Days after index discharge ___________________________

Appendix G
Patient Face Sheet
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Patient Face Sheet
Study Name: ___________________________________________________
Pt. Study ID #: ____________________
Pt. DOB: ___________________
(DD-MMM-YYYY)
Pt. Address: ____________________________________________________
____________________________________________________
Home Phone: ___________________________
Work Phone: ___________________________
Cell Phone: ___________________________
Spouse / Significant Other / Caregiver (circle one)
Address: ___________________________________________________
___________________________________________________
Home Phone: ___________________________
Work Phone: ___________________________
Cell Phone: ___________________________
Emergency Contact Name: _________________________________________
Phone #___________________

Appendix H
Pre-Hospitalization Variables and Associated Prediction of Inpatient
Hospitalization at 6-Month Follow-up
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Pre-Hospitalization Variables and Associated Prediction of Inpatient Hospitalization
at 6-Month Follow-up
6 Month
Inpatient
Admission
M(Sd)

No Inpatient
Admission at 6
Months
M(Sd)

df

t-score

P-value

Variable

N

Age

0=29
1=10

43.50(10.00)

42.03(12.10)

37

-.344

.733

Total # Prior
Hospitalizations

0=23
1=9

.80(1.32)

.62(1.32)

37

-.371

.713

Length of Index
Hospitalization

0=29
1=10

7.90(3.64)

9.07(3.87)

37

.835

.409

IIP

0=29
1=10

1.41(.54)

1.80(.90)

30

1.176

.249

MADRS

0=29
1=10

39.10(9.70)

44.84(8.72)

37

1.64

.110

BDI

0=28
1=10

30.89(10.83)

38.71(12.52)

35

1.68

.102

AAQ-II

0=28
1=10

31.00(8.37)

30.89(10.83)

36

.774

.444

ATQ-F

0=28
1=10

82.20(29.21)

117.79(28.13)

36

3.40

.002

ATQ-B

0=28
1=9

83.30(30.77)

106.32(29.57)

36

2.90

.044

EROS

0=28
1=9

20.56(7.14)

18.79(6.36)

35

-.706

.485

Multiple Axis I
Diagnoses

0=
1=

Co-morbid Axis
I & II

0=
1=

Exceeded IIP cut
score

0=23
1=9

9(.67)

23(.74)

30

.398

.693

Note: 0 = Not hospitalized within 6 months post index hospitalization 1= Hospitalized within 6 month post
index

Appendix I
During Index-Hospitalization Data and Associated Prediction of Inpatient
Hospitalization at 6-Month Follow-up
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During Index-Hospitalization Data and Associated Prediction of Inpatient Hospitalization
at 6-Month Follow-up

6 Month
Inpatient
Admission
M(Sd)

No Inpatient
Admission at 6
Months
M(Sd)

df

t-score

P-value

Variable

N

Post- MADRS

0=29
1=10

18.10(10.25)

22.96(11.98)

36

1.41

.261

Post - BDI

0=28
1=10

20.89(7.99)

24.00(16.35)

36

.546

.588

Post - AAQ-II

0=28
1=10

24.00(8.94)

27.61(11.57)

36

.893

.378

Post - ATQ-F

0=28
1=10

67.10(31.40)

91.71(35.68)

36

1.93

.062

Post - ATQ-B

0=28
1=9

69.20(69.20)

86.43(35.58)

36

1.34

.190

Post - EROS

0=28
1=9

26.40(26.40)

23.57(5.93)

36

-1.30

.201

RCI MARDS

0=28
1=10

21.00(12.67)

21.50(13.51)

36

.102

.919

RCI BDI

0=28
1=9

10.00(14.02)

14.71(14.99)

36

.833

.411

RCI ATQ-F

0=28
1=10

15.10(28.80)

26.07(36.15)

36

.313

.393

RCI ATQ-B

0=28
1=9

14.10(33.75)

19.89(38.31)

36

.512

.674

RCI AAQ-II

0=28
1=10

7.00(13.04)

6.57(10.71)

36

.480

.916

RCI EROS

0=28
1=9

-6.78(6.16)

-4.48(5.91)

36

1.00

.704

Note: 0 = Not hospitalized within 6 months post index hospitalization 1= Hospitalized within 6 month post
index

Appendix J
ACT Treatment Related Variables and Associated Prediction of Inpatient
Hospitalization at 6-Month Follow-up

109

110
ACT Treatment Related Variables and Associated Prediction of Inpatient Hospitalization
at 6-Month Follow-up

6 Month
Inpatient
Admission
M(Sd)

No Inpatient
Admission at 6
Months
M(Sd)

df

t-score

P-value

Variable

N

Treatment Time

0=7
1=6

156.17(98.85)

166.71(67.35)

11

-.60

.824

Number of ACT
Sessions

0=8
1=6

3.17(.74)

3.13(1.55)

12

.228

.953

Quality of ACT
Sessions

0=8
1=6

4.78(.96)

3.58(1.14)

12

2.24

.05*

Pre-post ∆ on
MADRS

0=8
1=6

25.71(11.16)

18.63(9.24)

12

-1.20

.253

Pre-post ∆ on BDI

0=8
1=5

9.40(12.12)

11.38(16.12)

12

.23

.819

Pre-post ∆ on
ATQ-F

0=8
1=6

19.50(37.44)

16.50(29.82)

12

-1.19

.870

Pre-post ∆ on
ATQ-B

0=8
1=6

26.17(34.27)

20.50(35.91)

12

-.30

.771

Pre-post ∆ on
AAQ-II

0=8
1=6

10.33(15.91)

2.75(7.51)

12

-1.19

.256

Pre-post ∆ on
EROS

0=7
1=5

-9.80(4.76)

-4.71(7.43)

10

1.34

.211

